PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine )
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 3, RANDOMIZE D, OBSERVER -BLIND ST UDY TO EVALUATE THE 
SAFETY, TOLERABILITY , AND IMMUNOGENICITY OF MULTIPLE 
PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE 
BNT162b
2AGAINST COVID -19 IN HEALTHY PARTICIPANT S 12 THROUGH 
50YEARS OF AGE AND THE SAFETY, TOL ERABILITY, AND 
IMMUNOGENICITY OF BNT162b2 RNA- BASED COVID -19 VACCINE 
CANDIDATES AS A BOOSTER DOSE IN HE ALTHY PARTICIPANTS 1 8 
THROUGH 50 YEARS OF AGE
Study Sponsor: BioNTech
Study Conducted By: Pfizer
Study Intervention Number: PF-07302048
Study Intervention Name: BNT162b2 RNA -Based COVID -19 Vaccine s
US IND Number: 19736
EudraCT Number: 2020- 002641- 42
Protocol Number: C459 1017
Phase: 3
Short Title: A Phase 3 Study  to Evaluate the Safety , Tolerability , and Immunogenicity  of 
MultipleProduction Lots and Dose Levels of BNT162b2 RNA -Based COVID -19 Vaccines 
Against COVID- 19 in Healthy  Partic ipants
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these document s, you agree to hold this information 
in confidence and not copy or disclose it to others (except where required by app licable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 3Because of the addition of participants 12 through 
17years of age, multisystem inflammatory syndrome in 
children is added as an AE of special interest.
Added the possibility of assessing S1 -binding instead of 
the full -length S -binding IgG levels.
Because of an increased incidence rate of SARS -CoV -2 
in the US, it is expected that more participants will be 
diagnosed with COVID -19 during their time in the 
study ;therefore ,the nonevaluable rate was increased 
from 15% to 20% .
The criterion to discontinue the study intervention at 
Dose 2 in participants who were diagnosed with 
COVID -19 betw een Visit 1 and Visit 2 has been 
removed ,as the ACIP recommends that vaccination 
should be offered to persons regardless of history of 
prior symptomatic or asymptomatic SARS -CoV- 2 
infection.
The exclusion criterion for immunocompromised 
individuals was inadvertently omitted and now appears 
as exclusion criterion 5.
The Benefit/Risk Assessment section has been upd ated 
to reflect the additional clinical data available for 
BNT162b2.  The Over all Benefit/Risk Conclusions 
section has notchanged.
A clarification was made in Section 8.1.1 , Biological 
Samples, that no testing of the participant’s DNA will be 
performed.
Original protocol 24Nov 2020 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 4TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................16
1.2.1. Primary  Study .............................................................................................16
1.2.2. Boost er Stud y
..............................................................................................17
1.3. Schedule of Activities .............................................................................................18
1.3.1. Primary  Study .............................................................................................18
1.3.2. Booster Stud y
..............................................................................................20
2. INTRODUCTION ...............................................................................................................22
2.1. Study  Rationa le.......................................................................................................22
2.2. Background .............................................................................................................22
2.2.1. Clinical Overview .......................................................................................24
2.3. Benefit/Risk Assessment
.........................................................................................24
2.3.1. Risk Assessment
.........................................................................................26
2.3.2. Ben efit Assessment .....................................................................................28
2.3.3. Overall Benefit/Risk Conclusion ................................................................28
3. OBJECTI VES, ESTIM
ANDS, AND ENDPOINTS ...........................................................28
3.1. Primary  Study ..........................................................................................................28
3.2. Booster Stud y
..........................................................................................................30
4. STUDY DESIGN .................................................................................................................31
4.1. Overall Design .........................................................................................................31
4.2. Scientifi c Rationale for Study  Design .....................................................................32
4.3. Justification for Dose ..............................................................................................32
4.4. End of Study  Definition ..........................................................................................32
5. STUDY POPUL ATION
................................ ................................ ................................ ......33
5.1. I nclusion Criteria .....................................................................................................33
5.2.Exclusion Criteria ....................................................................................................34
5.3. L ifesty le Considerations ..........................................................................................35
5.3.1. Contraception ..............................................................................................35

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 55.4. Screen Failures ........................................................................................................36
5.5. Criteri a for Temporarily  Delay ing Enrollment/Randomization/Study  
Intervention Administration (Primary  Study )
...........................................................36
6. STUDY INTERVENTIO N
..................................................................................................37
6.1. Study  Intervention(s) Administered ........................................................................37
6.1.1. Primary  Study .............................................................................................37
6.1.2. Boost er Stud y
..............................................................................................38
6.1.3. Administration ............................................................................................38
6.2. Preparation/Handling/Storage/Accountability ........................................................39
6.2.1. Preparation and Dispensing ........................................................................40
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................40
6.3.1. Allocation to Study Intervention ................................................................40
6.3.2. Blinding of Site Personnel ..........................................................................40
6.3.3. Blinding of the Sponsor
..............................................................................41
6.3.4. Breaking the Blind ......................................................................................41
6.4. Study  Intervention Compliance ...............................................................................42
6.5. Concomitant Therapy ..............................................................................................42
6.5.1. Prohibited During the Study .......................................................................42
6.5.2. Permitted During the Study ........................................................................43
6.6. Dose Modification ...................................................................................................43
6.7. I ntervention After the End of the Study  (Primary  Study )
.......................................43
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................43
7.1. Discontinuation of Study  Intervention (Primary  Study )
.........................................43
7.2. Participant Discontinuation/Withdrawal From the Study .......................................44
7.2.1. Withdrawal of Consent ...............................................................................45
7.3. L ost to Follow -
up ....................................................................................................45
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................46
8.1. I mmunogenicit y Assessments .................................................................................46
8.1.1. Biological Samples .....................................................................................47
8.2. Safet y Assessments .................................................................................................47
8.2.1. Clinical Safety  Laboratory  Assessments ....................................................48

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 68.2.2. Electronic Diary ..........................................................................................48
8.2.2.1. G rading Scales ...........................................................................48
8.2.2.2. L ocal Reactions .........................................................................48
8.2.2.3. Sy stemic Events ........................................................................49
8.2.2.4. Fever ..........................................................................................50
8.2.2.5. Antipy ret
ic/Analgesic Medication ............................................51
8.2.3. Pregnancy  Testing ......................................................................................51
8.3. Adverse Events and Serious Adverse Events
..........................................................51
8.3.1. Time Period and Frequency  forCollecting AE and SAE Information .......52
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................53
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
...................53
8.3.2. Method of Detecting AEs and SAEs ..........................................................53
8.3.3. Follow -up of AEs and SAEs .......................................................................53
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................53
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ................................ ................................ ................................ .......... 54
8.3.5.1. Exposure During Pregnancy ......................................................54
8.3.5.2. Exposure During Breastfeeding ................................................55
8.3.5.3. Occupational Exposure .............................................................56
8.3.6. Cardiovascular and Death Events ...............................................................56
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................56
8.3.8. Adverse Events of Special Interest .............................................................56
8.3.8.1. Lack of Efficacy ........................................................................57
8.3.9. Medical Device Deficiencies ................................ ................................ ......57
8.3.10. Medication Errors .....................................................................................57
8.4. Treatment of Overdose
............................................................................................58
8.5. Pharmacokinetics ....................................................................................................59
8.6. Pharmacod ynamics ..................................................................................................59
8.7. Genetics ...................................................................................................................59
8.8. Biomarkers ..............................................................................................................59
8.9. I mmunogenicit y Assessments .................................................................................59

PF-07302048 (BNT162b2 RNA-Ba sed COVID-19 Vaccine)
Protocol C4591017Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 78.10. Health Economics .................................................................................................59
8.11. Study P rocedures...................................................................................................59
8.11.1. Visit 1 – Vaccination 1 (Day 1)................................................................598.11.2. Visit 2 – Vaccination 2 (19 to 23 Days After Visit 1)..............................628.11.3. Visit 3 – 1-Month Follow-up (28 to 35 Days After Visit 2).....................64
Booster Study Procedures ..............................................................................................64
8.11.4. Visit 4 – Vaccination 3 (83 to 97 Days After Visit 2)..............................648.11.5. Visit 5 – 1-Week Follow-up (6 to 8 Days After Visit 4) ..........................678.11.6. Visit 6 – 1-Month Follow-up (28 to 35 Days After Visit 4).....................67
8.12. Unscheduled Visits for a Grade 3 or Suspected Grade 4 Reaction.......................68
9. STATISTICAL C ONSIDERATIONS ................................................................................69
9.1. Estimands and Statistical Hypotheses .....................................................................69
9.1.1. Estimands....................................................................................................699.1.2. Statistical Hypothesis..................................................................................70
9.2. Sample Size Determination.....................................................................................71
9.3. Analysis Sets ...........................................................................................................739.4. Statistical Analyses .................................................................................................74
9.4.1. General Considerations...............................................................................74
9.4.1.1. Analyses for Bi nary Data ..........................................................75
9.4.1.2. Analyses for Continuous Data...................................................75
9.4.2. Primary Endpoint(s)....................................................................................769.4.3. Secondary Endpoints ..................................................................................79
9.5. Interim Analyses .....................................................................................................799.6. Data Monitoring Committee or Other Independent Oversight Committee.............80
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................81
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............81
10.1.1. Regulatory and Ethical Considerations ....................................................81
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................81
10.1.2. Informed Consent Process ........................................................................82CCI
PF-07302048 (BNT162b2 RNA-Ba sed COVID-19 Vaccine)
Protocol C4591017Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 810.1.3. Data Protection .........................................................................................83
10.1.4. Dissemination of Clinical Study Data ......................................................8310.1.5. Data Qualit y Assurance ............................................................................84
10.1.6. Source Documents....................................................................................8610.1.7. Study and Site Start and Closure ..............................................................8610.1.8. Sponsor’s Qualified Medical Personnel ...................................................87
10.2. Appendix 2: Clinical Laboratory Tests .................................................................8810.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................89
10.3.1. Definition of AE .......................................................................................8910.3.2. Definition of SAE.....................................................................................9010.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................9210.3.4. Reporting of SAEs....................................................................................95
10.4. Appendix 4: Contraceptive Guidance ...................................................................96
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................9610.4.2. Female Participant Reproductive Inclusion Criteria.................................9610.4.3. Woman of Childbearing Potential ............................................................9710.4.4. Contraception Methods.............................................................................98
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up Assessments ......10010.6. Appendix 6: Abbreviations .................................................................................102
11. REFERENCES ................................................................................................................1 05
LIST OF TABLES
Table 1. Local Reaction Grading Scale ..................................................................49Table 2. Systemic Event Grading Scale..................................................................50Table 3. Scale for Fever..........................................................................................51
Table 5. Probability of Observing an Event Given a Specified Incidence 
Rate With 30 Participants per Group........................................................73
CCI
PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY
1.1. S ynopsis
Short Title:   A Phase 3 Study  to Evaluate the Safety , Tolerability , and Immunogenicit y of 
Multiple Production L ots and Dose Levels of BNT162b2 RNA -Based COVID - 19Vaccines
Against COVID -19 in Healthy  Participants
Rationale
A pneumonia of unknown cause detected in Wuhan, China, was first reported in 
December 2019.  InJanuary 2020, the pathogen causing this outbreak was identified as a 
novel coronavirus 2019.  The outbreak was declared a Public Health Emergency  of 
International Concern on 30 January 2020.  On 12 February  2020, the virus was officiall y 
named as severe acute respiratory  syndrome coronavirus 2 (SARS -CoV -2), and the WHO 
officiall y named the disease caus ed by SARS -CoV -
2 as coronavirus disease 2019 
(COVID -19).  On 11 March 2020, the WHO upgraded the status of the COVID- 19 outbreak 
from epidemic to pandemic, which is now spreading globall y at high speed.
Based on Phase 2/3 safety, immunogenicit y, and effica cy data, BNT162b2 was shown to be 
effective and has been authorized for temporary  or emergency  use in multiple countries.
BNT162b2 is administered intramuscularl y as a 2 -dose series spaced 21 day s apart at a dose 
of 30 μg each.  Study  C4591001 ([STUDY_ID_REMOVED]) is a n ongoing Phase 1/2/3 trial designed to 
generate safety , tolerability ,immunogenicity ,and efficacy data from a novel RNA -based 
vaccine candidate . The trial is being conducted in a 
heterogen eous study  population : eligible 
participants ≥12yearsof age , healthy  participants, including those participants with stable 
chronic medical conditions, as well as HIV -, HCV -,and HBV -positive participants. 
BNT162b2 was selected from the Phase 1 part of this study based on the overall safety , 
tolerability ,and immunogenicity .
To support distribut ion of this vaccine on a wider scale ,the study will evaluate the immune 
response across 4 different BNT162b2 lots manufactured at a commercial scale : 3lotsof 
drug substance manufactured in the United States and1lotof drug substance manufactured 
in Europe (Arms 1-4 ) and describe the safet y and tolerability  of these different vaccine lots in 
healthy  participants.
Whil ethe 30
-µg dose was selected based on favorable reactogenicit y and immunogenicit y in 
both y ounge r and older participants, Phase 1 immunogenicity  and safety  data were also 
robust with the 20 -µg dose in the y ounger population. Investigating the noninferiority  of a 
20-µg dose compared with the standard 30 -µg dose may support the potential use of a lower 
vaccine dose in the defined population of this study . This will be of value with the demand 
to vaccinate the general population. Therefore, a noninferiority  anal ysis will be performed in 
this study  of a 20-µ g dose against the standard 30 -µg dose.  The 20 -µg dose arm (Arm 5) will 
contain the same US -manufactured drug substance as one of the US lots in the study  and will 
be compared against that same lot in the noninferiority  analy sis.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 10Note:  I n this protocol, the US -manufactured drug substance lots a re also referred to as the 
“US lots” and the EU -manufactured drug substance lot is also referred to as the “EU lot. ”
In light of the unknowns regarding duration of protection, as well as the emerging variants of 
concern (VOCs), it is important to understan d the boostability  of BNT162 b2, and potential 
heterologous protection against emerging VOC(s).  To this end, a booster study extension has 
been added in protocol amendment 2 in which a small subset of adult participant s who 
received Doses 1 and 2 at 30 µg from a designated US lot(s) will receive a single dose of 
either 30 µg BNT162b2 or 30µg BNT162b2
.B.1.351 (BNT162b2s01 vaccine encoding for
thefull-length spike protein of South Africa variant B.1.35 1[formerl y known as 
BNT162b2 SA]). This third dose will be administered at approximately  3 months after Dose 2
ofBNT162b2 .

PF-07302048 (BNT162b2 RNA-Ba sed COVID-19 Vaccine)
Protocol C4591017Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 11Primary Study
Objectives, Estimands, and Endpoints
Objectives Estimands Endpoints
Primary Immunogenicity – Lot Comparisons
To demonstrate that the immune 
responses induced by BNT162b2 are similar across the 3 US lots (Arms 1,2, and 3) in participants without 
evidence of SARS-CoV-2 infection 
during the study.In participants complying with the key 
protocol criteria (evaluable participants):
• GMR from one US lot to another 
lot (Arm 1/Arm 2, Arm 1/Arm 3, and Arm 2/Arm 3) 1 month after 
Dose 2• Full-length S-binding IgG levels
To demonstrate that the immune 
response induced by the EU lot(Arm 4) of BNT162b2 is similar to 
the pooled US lots (Arms 1, 2, 
and 3) in participants without evidence of SARS-CoV-2 infection during the study.In participants complying with the key 
protocol criteria (evaluable participants):
• GMR from the EU lot (Arm 4) to
the pooled US lots (Arm 4/pooled Arms 1, 2, and 3) 1 month after 
Dose 2• Full-length S-binding IgG levels
Primary Immunogenicity – Dose Comparison
To demonstrate the noninferiority of
the immune response to prophylactic
BNT162b2 in participants receiving 
20 μg compared to participants
receiving the standard 30- μg dose
(prepared from the same 
manufacturing lot) without evidence 
of SARS-CoV-2 infection during the study.In participants complying with the key 
protocol criteria (evaluable 
participants):
• GMR, estimated by the ratio of the
geometric mean of SARS-CoV-2
neutralizing titers in the 2 dose 
groups 1 month after Dose 2• SARS-CoV-2 neutralizing titers
Primary Safety
To evaluate the safety of BNT162b2 
when administered on a 2-dose 
schedule in healthy participants12 through 50 years of age.In participants receiving at least 1 dose 
of study intervention from each vaccine 
group (individual and pooled US lots, EU lot, 20- μg dose), the percentage of 
participants reporting:
• Local reactions for up to 7 days
following each dose
• Systemic events for up to 7 days 
following each dose
• AEs and SAEs from Dose 1 to 
1 month after Dose 2• Local reactions (pain at the 
injection site, redness, and swelling)
• Systemic events (fever, fatigue, 
headache, chills, vomiting, diarrhea, new or worsened muscle 
pain, and new or worsened joint 
pain)
• AEs
• SAEsCCI
PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 12Secondary Immunogenicity
To describe the immune responses 
induced by different 30-µg dose 
manufacturing lots of BNT162b2.In evaluable participants from each 
vaccine group (individual and pooled 
US lots, EU lot):
 GMCs at baseline (before Dose 1) 
and 1 month after Dose 2
 GMFR from baseline (
before 
Dose 1)to 1 month after Dose 2 Full-length S-binding IgG levels
To describe the immune responses 
induced by different doses of 
BNT162b2.In evaluable participants from each 
vaccine group (20 µg and 30 µgfrom 
the same US lot ):
 GMCs at baseline (before Dose 1) 
and 1 month after Dose 2
 GMFR from baseline (before 
Dose 1) to 1 month after Dose 2 SARS -CoV -2 neutralizing titers
Note:  “US lots” refer sto the lots of study vaccine containing drug substance manufactured in the United States.  
“EU lot” refers to the lot of study vaccine containing drug substance manufactured in Europe.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 13Booster Study
Objectives Estimands Endpoints
Prim ary Safety
To evaluate the safety and 
tolerability profile of a third dose of 
study intervention (either BNT162b2 
30 µg orBNT162b2 .B.1.351 *
30µg),administered to participants 
(18 through 50 years of age) who 
received two 30-µg doses of 
BNT162b2 , approximately 3 months 
after Dose 2.In participants receiving the third dose 
of study intervention, the percentage of 
participants reporting:
 Local reactions for up to 7 days 
following the booster dose
 Systemic events for up to 7 days 
following the booster dose
 AEs and SAEs from the booster 
dose to 1 month after the booster 
dose Local reactions (pain at the 
injection site, redness, and 
swelling)
 Syste mic events (fever, fatigue, 
headache, chills, vomiting, 
diarrhea, new or worsened muscle 
pain, and new or worsened joint 
pain)
 AEs
 SAEs
Prim ary Immunogenicity
To describe the immune response 
induced by a third dose of study 
intervention (either BNT162b2
30µgorBNT162b2. B.1.351 *
30µg).In evaluable participants from each 
vaccine group (either BNT162b2 30 µg
orBNT162b2 .B.1.351 30 µg):
 Geometric mean neutralizing titer s
at baseline (before Dose 1), 
1month after Dose 2 , before 
Dose 3, and 1 wee k after and 
1month after Dose 3
 Geome tric mean IgG 
concentration sat baseline (before 
Dose 1), 1 month after Dose 2, 
before Dose 3, and 1 week after 
and 1 month after Dose 3
 GMFR sfrom 1 month after Dose 2 
to 1 week after and 
1 month after 
Dose 3 and from before Dose 3 to 
1 week after and 1 month after 
Dose 3
 The percentages of participants 
with seroresponse§(based on 
neutralizing titers) to the reference 
strain at 1 month after Dose 2 , 
before Dose 3, and1 week after 
and1 month after Dose 3
 Thepercentages of participants 
with seroresponse§(based on 
neutralizing titers) to the B.1.351
variant strain at 1 month after 
Dose 2, before Dose 3, and 1 week 
after and1 month after Dose 3 SARS -CoV -2 reference -strain 
neutralizing titer†
 SARS -CoV -2 B.1.351 -strain 
neutralizing titer††
 Full-length S -binding IgG levels
*BNT162 .B.1.351 = BNT162b2s01 vaccine encoding for the full-length spike protein of South African– origin variant 
B.1.351 (formerly BNT162b2 SA).
†SARS -CoV -2 reference -strain neutralizing titers = neutraliz ingtiters against SARS -CoV -2 USA -WA 1/2020 virus .
†† SARS -CoV -2 B.1.351-strain neutralizing titers = neutraliz ingtiters against SARS -CoV -2 virus with B.1.351 spike .
§ Seroresponse is defined as ≥4-fold increase from baseline (before Dose 1) to the specified time point. If the baseline 
measurement is below LLOQ, apostvaccination measure ment of ≥4 × LLOQ is considered a seroresponse .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 14Overall Design
This is a Phase 3, randomized, observer- blind study  to evaluate the safety, tolerability , and 
immunogenicit y of 4 manufactur ing lots 
of BNT162b2 as a30-µg dose andan additional
20-µgdos e arm using one of the same manufactured 30- µg lot s.BNT162b2 is an 
RNA -based COVID -19 vaccine, administered on a 2 -dose schedule in healthy  participants 
12through 5 0years of age.   Participants will be randomized to 1 of 5 arms in a 2:2:2:1:2 
ratio (Arm 1: Arm 2: Arm 3: Arm 4: Arm 5), where Arms 1, 2, and 3contain 
US-manufactured drug substance for 30 -µg dosing ;Arm 4contains EU-manufactured drug 
substance for 30 -µg dosing ;and Arm 5 contains US-manufactured drug substance for 20-µg
dosing.  In order to allow for balanced age representation across all arms ,the randomization 
will be stratified by age groups: 12 through 17, 18 through 30, and 31through 50years.
The duration of the study for each participant will be approximately  2 months. The study
will be conducted in the United States.
Protocol a mendment 2 has added a booster stud y in which a subset of the adult participants 
(18 through 50 years of age) who each received two 30-µg doses of the designated US lot(s) 
will be randomly  assigned to 1 of 
2arms in a 1:1 ratio (Booster 1: Booster 2), wher e 
Booster 1 is BNT162b2 at 30 µg andBooster 2 is BNT162b2 .B.1.351 at 30 µg. Thethird 
dose will be administered approximately  3 months after BNT162b2 Dose 2 of the primary  
study .
The duration of the booster study  for each participant will be approximately 1 month.  This 
study  is observer -blinded, to minimize changes in study  conduct compared with the primary  
study .
Number of Participants
Approximately  340 participants will be randoml y assigned to each of the 3 US lots (Arms
1-3) and to the 20 -µg arm(Arm 5) and approximately  170 participants will be randomly  
assigned to the EU lot (Arm 4)
,for a total of approximately  1530 randomized participants .  It 
is expected that approximately  1224 evaluable participants will complete the study , based on 
a 20% nonevaluable rate.
In the booster stud y, approximately  30 participants will be assigned to each arm for a total of 
60participants to be 
enrolled.  I t is expected that approximately  48evaluable participants 
will complete the study , based on a 20% nonevaluable rate.
Data Monitoring Committee or Other Independent Oversight Committee
This study  will use a DMC.  
The DMC is independent of the study team and includes 
external members.   The DMC charter describes the role of the DMC in more detail.
The DMC will be responsible for ongoing monitoring of the safety  of participants in the 
study  according to the charter.  This may  include, but is not limited to:

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 15Contemporaneous review of related AEs up to 1 month after completion of the 
vaccination schedule ,
Contemporaneous review of all SAEs up to 1 month after completion of the 
vaccination schedule .
The recommendations made b y the DMC to alter the conduct of the stud y will be forwarded 
to the appropriate Pfizer personnel for final decision.  Pfizer will forward such decisions, 
which may  include summaries of aggregate analy ses of safety  data, to regulatory  authorities, 
as appropriate.
Statistical Methods
There are 2 primary  immunogenicity  objectives on manufacturing lot comparison s. The first 
primary  immunogenicity  objective will be evaluated by  formal hy pothesis tests for 
consistency  of the immune response induced b y BNT162b2 30 µg across the 3 US lots . 
GMRs of the f ull- length S- binding IgG levels and their 2 -sided 95% CIs will be provided for 
each pair of between -lot comparisons ( Arm 1to Arm 2, Arm 1to Arm 3, and Arm 2to 
Arm 3)using a 1.5-fold equivalence margin .  Two lots will be conside redsimilar if the 
2-sided 95% CI for theGMR is contained in the interval (0.67, 1.5 ).  Overall, t helots will be 
considered similar if the 1.5 -fold equivalence criterion is met for all 3 between -lot 
comparisons ( Arm 1to Arm 2, Arm 1to Arm 3, and Arm 2to Arm 3).
The second prim ary immunogenicity  objective of simila ritybetween the EU lot 
andthe 
3pooled US lots will be assessed sequentially  after the first primary  objective is met .Using 
a 1.5 -fold equivalence margin, the EU lot and the pooled US lots will be considered similar if 
the 2
-sided 95% CI for the GMR of the full -length S -binding IgG lev elsis contained in the 
interval (0.67, 1.5).
The primary  immunogenicity  objective of noninferiority  of the BNT162b2 20-µg vs 30 -µg
dose levels
, using a 1.5-fold noninferiority  margin, will be achieved if the lower limit of the 
2-sided 95% CI for the GMR of the SARS- CoV -2 neutralizing titers is >0.67.
With 270 evaluable participants per US lot, the study  has a power of 91.7 % for conside ring 
the 3 US lots to be similar . The stud y will also provide 92.8% power for conside ring the EU 
lot similar to the US l ots, with 135 evaluable participants in the EU lot and 810 evaluable 
participants in the pooled US lots. With 270 evaluable participants for the 20 -µg and 30 -µg 
dose groups ( Arm 5 and the corresponding US 30- µg lot [Arm 1, 2, or 3]) , the study  will 
have a power of 
94.7% fordeclaring noninferiority .  Assuming a nonevaluable rate of 20%, 
the study  will randomize approximately  340 participants in each US lot, 170 participants in 
the 
EU lot , and 340 partici pants in the 20-µg dose group to achieve the required evaluable 
participants.
The secondary immunogenicity  objective s
will be evaluated descriptivel y by GMCs ,
GMFRs , and the associated 95% CIs for the full -length S -binding IgG levels for Arms 1

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine )
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 16through 4and GMTs, GMFRs ,and the assoc iated 95% CI s for the SARS -CoV -2 neutralizing 
titers for Arm 5 and the corresponding US 30-µg lot(Arm 1, 2,or 3).
The primary safet y objective will be evaluated by descriptive statistics including counts and 
percentages of participants and the associated Clopper -Pearson 95% CIs for local reactions, 
systemic events ,and AEs/SAEs, for each vaccine group .
In the booster stud y, the primary  immunogenicity  objectives w ill be evaluated descriptivel
y 
by GMCs, GMFRs, and the associated 95% CIs for the full -length S -binding IgG levels and 
by GMTs, GMFRs, and the associated 95% CIs for the SARS -CoV -2 neutralizing titers for 
both the reference strain and the B.1.351 strain for each vaccine group.  Additionally , the 
percentage of participants with a seroresponse to the reference strain andB.1.351 strain using 
neutralizing titers will be summarized.
The primary  safet y objective will be evaluated b y descriptive statistics includ ing counts and 
percentages of participants and the associated Clopper -Pearson 95% CIs for local reactions, 
systemic events, and AEs/SAEs, for each vaccine group.
1.2.Schema
1.2.1. Primary Study
a.Arms 1 through 3 are administered a30-µg dose level of manufacturing lots 1 through 3, respectively, 
containing US -manufactured drug substance.
b.Arm 4 is administered a 30-µg dose level of manufacturing lot 4, containing EU -manufactured drug substance.
c.Arm 5 is administered a 20-µg dose level from the cor responding US lot (Arm 1, 2 ,or 3).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine )
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 171.2.2. Booster Study

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 222.INTRODUCTION
BNT162b2 is anRNA -based COVID -19 vaccine that is currentl y being investigated for the 
prevention of COVID -19 in individuals ≥12 y earsof age .
2.1.Study Rationale
One aim of the stud y is to demonstrate th at a similar immune response is induced by  4lots of 
BNT162b2 (3 containing drug substance manufactured in the U
nited States , referred to as the 
“US lots ,”and1containing drug substance manufactured in Europe , referred to as the “EU 
lot”),and describe the safety  and tolerability  of these different vaccine lots in hea lthy 
participants, thereb y supporting both US and EU manufacturing process es at commercial 
scale .One of the US lots will also be administered at a 20-µg dose and compared with the 
standard 30
-µg dose from the same US production lot in a noninferiority  analy sis.This 
objective will support the potential use of a lower vaccine dose in the defined study  
population, which will be of value, given the demand to vaccinate the general population.
As more data about COVID -19 continue to accrue, the potential duration of protection 
afforded after a wild -type SARS -CoV -2 infection, and by  vaccination, remains unknown. If 
a third dose of BNT162b2 becomes necessary , whether it be with the current vaccine or one 
encoding for a VOC , it will be important to understand the safet y and immunogenicity  when 
the third dose is administered in close proximity  to the second dose.
2.2.Background
In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China.  
InJanuary  2020, it became clear that a novel coronavirus (2019 -nCoV) was the underl ying 
cause.  Later in January , the genetic sequence of the 2019 -nCoV became available to the 
WHO and thepublic (MN908947.3), and the virus was categorized in the Betacoronavirus
subfamily .  By  sequence anal ysis, the phy logenetic tree revealed a closer relationship to 
SARS virus isolates than to another coronavirus infecting humans, the MERS virus.1,2
The outbreak was declared a Public Health Emergency  of International Concern on 
30January 2020.3  On 12 February  2020, the virus w as officiall y named as severe acute 
respiratory  syndrome coronavirus 2 (SARS -CoV -2), and the WHO officially named the 
disease caused b y SARS -CoV -2 as coronavirus disease 2019 (COVID -19).3SARS -CoV -2 
infections and the resulting disease, COVID -19, have spread globall yand o n 11 March 2020, 
the WHO characterized the COVID -19 outbreak as a pandemic.4On 08 January  2021, t he 
Cent er for S ystems Science and Engineering at Johns Hopkins University  reported more than 
88million cases globall y, with over 
1.9million deaths from 191countries. The 
United States has reported 21.6 million cases and over 366,000 deaths.5  Since fall of 20 20,
the incidence of COVID -19 illnesses is increasing dramaticall y in man y northern hemisphere 
countries ,including the United States, France, Germany , Italy, and the United Kingdom ,
raising the specter that as temperatures fall and the “respiratory  virus season” starts, cases 
may dramaticall y increase, potentially overwhelming healthcare infrastructures. This 
possibility  highlights the importance of developing a COVID -19 vaccine as quickly  as 
possible while en suring that all safet y measures are met.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 23Based on Phase 2/3 safety, immunogenicit y, and efficacy data, BNT162b2 was shown to be 
effective and has been authorized for temporary  or emergency  use in multiple countries.
As more data about COVID -19 continue to accrue, the potential duration of protect ion 
afforded after a wild -type SARS -CoV -2 infection, and by  vaccination, remains unknown. In 
addition, mutated SARS -CoV -2 VOCs have started to emerge, for example ,B.1.1.7
(alsoknown as 20I/501Y.V1, VOC 202012/01 [UK origin] ), B.1.351 (also known as 
20H/501Y.V2 [South Africa origin] ), and P.1 (also known as 20J/501Y.V3 [Brazil origin] ).6
A proph ylactic, RNA -based SARS -CoV -2 vaccine provides one of the most flexible and 
fastest approaches available to immunize against the emerging virus.7,8
The development of an RNA -based vaccine encoding a viral antigen, which is then expressed 
by the vaccine recipient as a protein capable of eliciting protective immune responses, 
provides significant advantages over more traditional vaccine approaches.  Unlike live 
attenuated vaccines, RNA vaccines do not carry  the risks associated with infection and may  
be given to people who cannot be administered live virus (eg, pregnant women and 
immunocompromised persons).  RNA -based vaccines are manufactured via a cell- free 
invitro transcription process, which allows an easy and rapid production and the prospect of 
producing high numbers of vaccination doses within a shorter time period than achieved with 
traditional vaccine approaches.  This capability  is pivotal to enable the most effective 
response in outbreak scenarios.7,8
In an attempt to prevent the spread of disease and to control the pandemic, numerous 
COVID -19 vaccine candidates are in development.  Two SARS -CoV - 2–RNA lipid 
nanoparticle (RNA -LNP) vaccines b ased on a platform of nucleoside -
modified messenger 
RNA (modRNA, BNT162b2) will be evaluated in this study .  Each vaccine candidate 
expresses 1 of 2 antigens:
Primary and booster studies:  BNT162b2 (variant RBP020.2): modRNA encoding the 
Wuhan -Hu-1 referen ce1SARS -CoV -2 full -length, P2 mutant, prefusion spike 
glycoprotein (P2 S) (version 9);
Booster study:  BNT162b2s01 (variant RBP020.11): modRNA as above, but encoding 
the P2 S containing B.1.351 variant–specific mutations (South Africa origin) , as a 
representative VOC formerly  referred to as BNT162b2 SA, hereafter referred to as 
BNT162b2.B.1.351
.
In light of the unknowns regarding duration of protection, as well as the emerging VOCs, it is 
important to understand the boostability  of BNT162, and potential heterologous protection 
against emerging VOC(s).  To this end, a booster study  extension has been added in protocol 
amendment 2 in which a small s ubset of adult participants who received Doses 1 and 2 at 
30µg from a designated US lot (s)will receive a single dose of either 30 µg BNT162b2 or
30µg BNT162b2.B.1.351.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 242.2.1. Clinical Overview
Given clinical data from other similarly  formulated unmodified m essenger RNA liposomal 
vaccines from BioNTech in oncology  trials9and recent published results from clinical trials 
using modRNA influenza vaccines b y Moderna,10the BNT162 vaccines were expected to 
have a favorable safety profile with mild, localized, and transient effects.  BNT162 vaccines 
based on modRNA have now been administered to humans for the first time in Study 
C4591001 ([STUDY_ID_REMOVED]) and the BNT162- 01 study  conducted in Germany  by BioNTech, 
at doses between 1 µg and 100 µg.  The currently available safet y and immunogenicity data 
are presented in the BNT162 IB.11
2.3.Benefit/Risk Assessment
There is an ongoing global pandemic of COVID -19and, based on the data available from the 
C4591001 study , multiple temporary  or emergency  use authorizations and condit ional 
marketing authorizations have been granted for BNT162b2. The available safet y and 
immunogenicit y data from the ongoing Pfizer/BioNTech clinical trial combined with 
available nonclinical data with BNT162 vaccines, and data from nonclinical studies an d 
clinical trials with the same or related RNA components, or antigens, support a favorable 
benefit/risk profile and support continued clinical development of BNT162b2.
In the C4591001 stud y, BNT162b2 has been shown to elicit increased local and systemic 
adverse reactions as compared to those in the placebo arm, usuall y lasting a few days. The 
most common solicited adverse reactions were injection site pain (84.1%), fatigue (62.9%), 
headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%) ,
and injection site swelling (
10.5%).11  Adverse reactions characterized as reactogenicit y were 
generall y mild to moderate. The number of participants reporting hy persensitivity -
related 
AEs was numerically  higher in the vaccine group compared with the placebo group (137 
[0.63%] vs 111 [0.51%]). Severe adverse reactions occurred in 0.0 % to 4.6% ofparticipants, 
were more frequent after Dose 2 than after Dose 1 ,and were generall y less frequent in older 
adults (>55 years of age) (<2.8%) as compared to y ounger participants ( ≤4.6%). Among 
reported unsolicited AEs, ly mphadenopathy  occurred much more frequentl y in the vaccine 
group than the placebo group and is plausibly  related to vaccination. SAEs, while 
uncommon (<1.0%), represented medical events that occur in the general population at 
similar frequency  as observed in the study .11
No specific safet y concerns were identified in subgroup anal yses by age, race, ethnicit y, 
medical comorbidities, or prior SARS -CoV -2 infection. Although participants 16 through 
17years of age were enrolled in the Phase 3 trial, safet y data for this age group are limited. 
However, available data are c onsistent with the safety  profile in the adult population, and it is 
biologicall y reasonable to extrapolate the greater safet y experience in adults, in particular 
younger adults, to the oldest pediatric age group of 12 through 17 years.  The potential risk s 
are based on the observed safet y profile to date, which shows mostly  mild reactogenicity , low 
incidence of severe or serious events, and no clinically  concerning safet y observations. The 
preponderance of severe cases of COVID -
19 in the placebo group rel ative to the BNT162b2 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 25group (9 of 10) suggests no evidence of VAED.11  Continued clinical investigation is 
justified given:
the urgent need for the development of a more stable proph ylactic vaccine for 
COVID -
19,
the threat posed b y the increasing number of glob ally distributed outbreaks of
SARS -CoV -2 infection and emerging VOCs,
the potential of the BioNTech platform of RNA -based vaccines to rapidl y deliver high 
numbers of vaccine doses in a single production campaign.
More detailed information about the known a nd expected benefits and risks and reasonabl y 
expected AEs of BNT162b2 may  be found in the IB,11which is the SRSD for this study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 262.3.1. Risk Assessment
Identified/Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention: BNT162b2 RNA -Based COVID- 19 Vaccine
Local and systemic reactions to the vaccine may 
occur (injection site redness, injection site swelling, 
and injection site pain; fever, fatigue, headache, 
chills, muscle pain, and joint pain) following 
vaccination.These are common adverse reactions seen with 
other vaccines12as well as the COVID -19 vaccine. 
The most common events reported in the C4591001 
study were mild to moderate pain at the injection 
site, fatigue ,and headache.The study employs the use of a reactogenicity 
e-diary to monitor local reactions and systemic 
events in real time.
All study part icipants will be observed for at 
least 30 minutes after vaccination.
Safety profile of a novel vaccine not yet fully 
characterized.
Adverse reactions (risks) identified from the 
postauthorization safety data include: 
Anaphylaxis, other hypersensitivity r eactions 
(eg,rash, pruritus, urticaria, angioedema), pain in 
extremity (injected arm) , vomiting, diarrhea.Data available from the C4591001 study showed 
low incidence of severe or serious events, and no 
clinically concerning safety observations across the
safety population and within demographic 
subgroups based on age, sex, race/ethnicity, 
country, and baseline SARS -CoV -2 status.
Postauthorization safety data surveillance has 
confirmed the safety profile observed in C4591001 
and has resulted in identificat ion of some additional 
adverse reactions (risks) as noted in this table.Collection of AE and SAE reports from signing 
of the ICD to 1 month after the second dose of 
vaccine.
DMC throughout the study to review all safety 
data.
All participants will be obse rved for at least 
30minutes after vaccination.
Theoretical risk for COVID -19 enhancement. Disease enhancement has been seen following 
vaccination with RSV, feline coronavirus, and 
Dengue virus vaccines. It is a modified and/or 
severe presentation of an infectious disease 
affecting individuals exposed to the wild -type 
pathogen after having received vaccine designed to 
prevent infection. No evidence of disease 
enhancement has been seen in large -scale clinical
study of BNT162b2 in humans or in 
postauthorization surveillance.Monitoring for cases of COVID -19 developing 
during the study, which will be reported as AESIs.   
Assessments of individual cases for disease 
enhancement is challenging based on current 
under standing of mechanism of pathogenesis, thus 
evaluations of any adverse or unexpected 
imbalances in severe COVID -19 cases may provide 
insight to a potential signal for this theoretical risk.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 27Identified/Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Primary study :  Multisystem inflammatory 
syndrome in children (MIS -C)Febrile hyperinflammatory condition with 
multisystem ( ≥2 organs) involvement as defined in 
Section 8.3.8 .MIS-C will be collected as an AESI for the duration 
of study participation.
Study Procedures
Participants will be required to attend healthcare 
facilities during the global SARS -CoV -2 pandemic.Without appropriate social distancing and PPE, 
there is a potential for increased exposure to 
SARS -CoV- 2.Pfizer w ill work with sites to ensure 
appropriate COVID -19 prevention strateg ies.
Monitoring for cases of COVID -19 developing 
during the study, which will be reported as 
AESIs.
Venipuncture will be performed during the study. There is the risk of bleeding, bruising, hematoma 
formation, and infection at the venipuncture site.Only appropriately qualified personnel will obtain 
the blood draw .

PF-07302048 (BNT162b2 RNA-Ba sed COVID-19 Vaccine)
Protocol C4591017Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 282.3.2. Benefit Assessment
Benefits to individual participants may include:
•Receipt of an efficacious or potentially efficacious COVID-19 vaccine during a global 
pandemic
•Access to COVID-19 diagnostic testing
•Contributing to research to help others in a time of global pandemic
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures taken to minimize risk to participants participating in this 
study, the potential risks identified in association with BNT162b2 are justified by the anticipated benefits that may be afforded to healthy participants.
3. OBJECTIVES, ESTIMANDS, AND ENDPOINTS
3.1. Primary Study
Objectives Estimands Endpoints
Primary Immunogenicity – Lot Comparisons
To demonstrate that the immune 
responses induced by BNT162b2 are 
similar across the 3 US lots (Arms 1, 
2, and 3) in participants without evidence of SARS-CoV-2 infection during the study.In participants complying with the key 
protocol criteria (evaluable 
participants):
• GMR from one US lot to another 
lot (Arm 1/Arm 2, Arm 1/Arm 3, and Arm 2/Arm 3) 1 month after Dose 2• Full-length S-binding IgG levels
To demonstrate that the immune 
response induced by the EU lot 
(Arm 4) of BNT162b2 is similar to the pooled US lots (Arms 1, 2, and 3) in participants without evidence of SARS-CoV-2 infection 
during the study.In participants complying with the key 
protocol criteria (evaluable 
participants):
• GMR from the EU lot (Arm 4) to 
the pooled US lots (Arm 4/pooled Arms 1, 2, and 3) 1 month after Dose 2• Full-length S-binding IgG levels
Primary Immunogenicity – Dose Comparison
To demonstrate the noninferiority of 
the immune response to prophylactic BNT162b2 in participants receiving 20 μg compared to participants 
receiving the standard 30- μg dose 
(prepared from the same 
manufacturing lot) without evidence of SARS-CoV-2 infection during the study.In participants complying with the key 
protocol criteria (evaluable participants):
• GMR, estimated by the ratio of the 
geometric mean of SARS-CoV-2 neutralizing titers in the 2 dose groups 1 month after Dose 2• SARS-CoV-2 neutralizing titersCCI
PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 29Objectives Estimands Endpoints
Prim ary Safety
To evaluate the safety of BNT162b2
when administered on a 2 -dose 
schedule in healthy participants 
12through 50 years of age.In participants receiving at least 1 dose 
of study intervention from each vaccine 
group (individual and pooled US lots, 
EU lot, 20 -µg dose), the percentage of 
participants reporting:
 Local reactions for up to 7 days 
following each dose
 Systemic events for up to 7 days 
following each dose
 AEs and SAEs from Dose 1 to 
1month after Dose 2 Local reactions (pain at the 
injection site, redness, and 
swelling)
 Systemic events (fever, fatigue, 
headache, chills, vomiting, 
diarrhea, new or worsened muscle 
pain, and new or worsened joint 
pain)
 AEs
 SAEs
Secondary Immunogenicity
To describe the immune responses 
induced by different 30 -µg dose 
manufacturing lots of BNT162b2.In evaluable participants from each 
vaccine group (individual and pooled 
US lots, EU lot):
 GMCs at baseline (before Dose 1) 
and 1 month after Dose 2
 GMFR from baseline (before Dose 
1) to 1 month after Dose 2 Full-length S -binding IgG levels
To describe th e immune responses 
induced by different doses of 
BNT162b2.In evaluable participants from each 
vaccine group (20 µg and 30 µg from 
the same US lot):
 GMCs at baseline (before Dose 1) 
and 1 month after Dose 2
 GMFR from baseline (before Dose 
1) to 1 month after Dose 2 SARS -CoV -2 neutralizing titers
Note:  “US lots” refer sto lots of study vaccine containing drug substance manufactured in the United States.  
“EU lot” refers to the lot of study vaccine containing drug substance manufactured in Europe.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 303.2.Booster Study
Objectives Estimands Endpoints
Prim ary Safety
To evaluate the safety and 
tolerability profile of a third dose of 
study intervention (either BNT162b2 
30 µg orBNT162b2.B.1.351* 30 µg) 
administered to participants 
(18through 50 years of age) who 
received two30-µg doses of 
BNT162b2 ,
approximately 3 months 
after Dose 2.In participants receiving the third dose 
of study intervention, the percentage of 
participants reporting:
 Local reactions for up to 7 d ays 
following the booster dose
 Systemic events for up to 7 days 
following the booster dose
 AEs and SAEs from the booster 
dose to 1 month after the booster 
dose Local reactions (pain at the 
injection site, redness, and 
swelling)
 Systemic events (fever, fati gue, 
headache, chills, vomiting, 
diarrhea, new or worsened muscle 
pain, and new or worsened joint 
pain)
 AEs
 SAEs
Prim ary Immunogenicity
To descri bethe immune response 
induced by a third dose of study 
intervention (either BNT162b2 
30µgorBNT162b2 .B.1.351 *
30µg).In evaluable participants from each 
vaccine group (either BNT162b2 30 µg
orBNT162b2. B.1.351 30 µg):
 Geometric mean neutralizing titers 
at baseline (before Dose 1), 
1month after Dose 2, before 
Dose 3, and 1week after a nd 
1month after Dose 3
 G
eometric mean IgG 
concentration sat baseline (before 
Dose 1), 1 month after Dose 2, 
before Dose 3, and1 week after 
and 1 month after Dose 3
 GMFR sfrom 1 month after Dose 2 
to 1 week after and 1 month after 
Dose 3 and from before Dose 3 to 
1 week after and 1 month after 
Dose 3
 The percentages of participants 
with seroresponse§(based on 
neutralizing titers) to the reference 
strain at 1 month after Dose 2, 
before Dose 3, and 1 week after 
and 1 month after Dose 3
 The percentages of participants 
with seroresponse§(based on 
neutralizing titers) to the B.1.351
variant strain at 1 month after 
Dose 2, before Dose 3, and 1 week 
after and 1 month after Dose 3 SARS -CoV -2 reference -strain 
neutralizing titer†
 SARS -CoV -2 B.1.351 -strain
neutralizing titer††
 Full-length S -binding IgG levels
* BNT162.B.1.351 = BNT162b2s01 vaccine encoding for the full-length spike protein of South African– origin variant 
B.1.351 (formerly BNT162b2 SA).
†SARS -CoV -2 reference -strain neutralizing titers = neutraliz ingtiters against SARS -CoV -2 USA -WA1/2020 virus .
†† SARS -CoV -2 B.1.351 -strain neutralizing titers = neutraliz ingtiters against SARS -CoV -2 virus with B.1.351 spike .
§ Seroresponse is defined as ≥4-fold increase from baseline (before Dose 1) to the specified time point. If the baseline 
measurement is below LLOQ, a postvaccination measure ment of ≥4 ×LLOQ is considered a seroresponse .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 314.STUDY DESIGN
4.1.Overall Design
Primary Study
This is a Phase 3, randomized, observer- blind study  to evaluate the safet y, tolerability , and 
immunogenicit y of 4 manufacturing lots of BNT162b2 as a30-µg dos e andan additional 
20-µg dos e arm using one of the same manufactured 30 -µg lots .  BNT162b2 is an
RNA -based COVID -19 vaccine, administered on a 2 -dose schedule in healthy  participants 
12through 50 years of age.  The study  will be conducted in the United States.
Participants will be randomized to 1 of 5 
arms in a 2:2:2:1:2 ratio (Arm 1: Arm 2: Arm 3: 
Arm 4: Arm 5), where Arms 1, 2, and 3 contain US- manufactured drug substance for 30 -µg 
dosing; Arm 4 contains EU -manufactured drug substance for 30 -µg dosing; and Arm 5 
contains US -manufactured drug substance for 20 -µg dosing.  In order to allow for balanced
age representation across all arms ,the randomization will be stratified by  age group s: 
12through 17, 18 through 30, and 31through 50 years.
The duration of the study for each participant will be approximately  2 months. This study  is 
observer -blinded, as the volumes of the 20 -µg and the 30 -µg doses of investigational vaccine 
arediffer ent.
Approximately  340 participants will be randoml y assigned to each of the 3 US lots ( Arms 
1-3) and to the 20 -µg arm(Arm 5) and approximately  170 participants will be randomly  
assigned to the EU lot ( Arm 4), for a total of approximately  1530 randomized participants.  It 
is expected that approximately
 1224 evaluable participants will complete the study , based on 
a 20% noneva luable rate.
Booster Study
Protocol a mendment 2 has added a booster stud y in which a subset of the adult participants
(18 through 50 years of age) who each received two30-µg doses of the designated US lot (s) 
will be randomly  assigned to 1 of 2 arms in a 1 :1 ratio (Booster 1: Booster 2), where 
Booster 1 is BNT162b2 at 30 µg and Booster 2 is BNT162b2.B.1.351 at 30 µg. The third 
dose will be administered approximately  3 months after BNT162b2 Dose 2 of the primary  
study .
Approximately  30 participants will be assigned to each arm for a total of 60participants 
enrolled.  It is expected that approximately  48evaluable participants will complete the study , 
based on a 20% nonevaluable rate.
The duration of the stud y for each p articipant will be approximately  1 month.  This study  is 
observer -
blinded, to minimize changes in study  conduct compared with the primary  study .  
This facilitates the start of a booster stud y with the third dose to be given 3 months after the 
receipt of Do se 2.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 324.2.Scientific Rationale for Study Design
This study  contains assessments that could be con sidered standard for a vaccine stud y.  
Blood samples taken for immunogenicit y will establish the level of immune response elicited 
by each armto provide the necessary
 data to meet the primary  endpoint sof the study . 
Immunogenicit y will be assessed b y the full-length S-binding IgG assay and 2SARS -CoV -2 
neutralization assay s, one with the reference strain and the second with the B.1.351 strain.
To establish if a participant has asy mptomatic SARS -CoV -2 infection, nasal swabs for 
SARS -CoV -2 nucleic acid amplification testing ( ie,NAAT) and blood samples to measure 
N-binding antibody levels will be taken.  A positive result on either test will result in the 
immunogenicit y data from that participant being excluded from the evaluable portion of the 
study  population.
  All reactogenicity  and safet y assessments are standard for a study  of this 
nature.
This study  will not include a p lacebo ,as the aim and design of this study  is not to 
demonstrate efficacy .
Human reproductive safety  data are not available 
forBNT162b2 , but there is no suspicion of 
human teratogenicit y based on the intended mechanism of action of the compound.
Therefo re, the use of a highl y effective method of contraception is required (see Appendix 4 ).
4.3.Justification for Dose
Based on data from the Phase 1 component of clinical trial C4591001, after administration of 
Dose 1 and prior to administration of Dose 2, BNT162b2 showed modest increases in 
SARS -CoV -2 neutralizing GMTs over baseline across dose levels (10µg, 20 µg , and 30 µg)
in both younger and older groups. Overall, BNT162b2 elicited h igher antigen -binding and 
neutralizing responses in younger participants than in older participants. The boost effect 
after receiving Dose 2 was most pronounced at the 30-µg dose level for older participants, 
hence its selection as the dose for Phase 2/3 evaluation .1
1  These data also support 
investigating the lower dose of 20 µg in this y ounger study  population , as the measured 
immune responses in b oth the 20-µg and 30-µg cohorts were similar with regard to the 
younger age group .
As this 30
-µg dose was approved in multiple countries for EUA , the additional booster dose 
will be administered at the same dose .
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases 
(asapplicable) of the respective 
study (primary , booster) into which he/she isenrolled,
including the last visit.
The end of the study is defined as the date of th e last visit of the last participant in the booster 
study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 335.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled.  The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviatio ns to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1.Primary  study : Male or female participants between the ages of 12and 50 years, 
inclusive, at Visit 1 ( Day 1).
Booster stud y: Male or female participants between the ages of 18 and 50 years, 
inclusive, at rerandomization .
Refer to Appendix 4 for reproductive criteria for ma le (Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Dis ease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment plan, 
laboratory  tests, lifest yle considerations, and other study  procedures.
3.Health y participants who are determined b y medical history, ph ysical examination 
(ifrequired), and clinical judgment of the investigator to be eligible for inclusion in the 
study .
Note: Healthy  participants with preexisting stable disease, defined as disease not 
requiring significant change in therap y or hospitalization fo r worsening disease during 
the 6 weeks before enrollment, can be included.
Informed Consent:
4.Capable of giving personal signed informed consent /have 
parent(s) /legal guardian
capable of giving signed informed consent as described in Appendix 1, which includes 
compliance with the requirements and restrictions listed in the I CDand in this protocol.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 345.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria appl y:
Medical Conditions:
1.Other medical or psy chiatric condition including recent (within the past year) or active 
suicidal ideation /behavior or laboratory  abnormality  that may  increase the risk of study  
participation or , in the investig ator’s judgment ,make the participant inappropriate for the 
study .
2.Known infection with HIV, HCV, or HBV.
3.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  intervention(s).
4. Previous clini cal (based on COVID -19 s ymptoms/signs alone, if a SARS -CoV -2 NAAT 
result was not available) or microbiological (based on COVID-19 s ymptoms/signs and a 
positive SARS -CoV -2 NAAT result) diagnosis of COVID -
19.
5. Immunocompromised individuals with known or suspe cted immunodeficiency , as 
determined b y history  and/or laboratory /physical examination.
6. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
7.Women who are pregnant or breastfeeding.
Prior/Concomitant Therapy:
8.Primary  study : Previous vaccination with any  coronavirus vaccine.
Booster stud y: Previous vaccination with any  coronavirus vaccine outside of this study .
9.Receipt of medications intended to prevent COVI D-19.
10. Individuals who receive treatment with radiotherapy  or immunosuppressive therapy , 
including cytotoxic agents or sy stemic corticosteroids (if sy stemic corticosteroids are 
administered for ≥14 days at a dose of ≥20 mg/day  of prednisone or equivalent) , eg,for 
cancer or an autoimmune disease, or planned receipt throughout the study .  
Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or ey es) corticosteroids are 
permitted.
11.Receipt of blood/plasma products or immunoglobulin, from 60 day s before study  
intervention administration or planned receipt throughout the stud y.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 35Prior/Concurrent Clinical Study Experience:
12.Participation in other studies involving study  intervention within 28 day s prior to study  
entry  and/or during study participation.
13. P revious participation in other studies involving study intervention containing LNP s.
Other Exclusions:
14. Investigat orsite staff or Pfizer /BioNTech employees directly  involved in the conduct of 
the study , site staff otherwise supervised by  the investigator, and their respective famil y 
members .
Additional Exclusion Criteria Specific to the Booster Study:
1.Current febrile illness (body  temperature ≥100.4°F [≥38.0°C]) or other acute illness 
within 48 hours before study  intervention administration.
2.Receipt of an y seasonal or pandemic influenza vaccine within 14 day s, or any  other 
nonstudy  vaccine within 28 days, before study  intervention administration.
3. Anticipated receipt of any seasonal or pandemic influenza vaccine within 14 day s, or any  
other nonstudy  vaccine w ithin 28 day s, after study  intervention administration.
4.Receipt of short -term (<14 day s) systemic corticosteroids.  Inhaled/nebulized, intra -
articular, intrabursal, or topical (skin or ey es) corticosteroids are permitted .
5.3.Lifestyle Considerations
5.3.1. Contracep tion
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of co ntraception methods 
(seeAppendix 4 ,Section 10.4.4) and will confirm that the participant has been instructed in 
its consistent and correct use.
At time points indicated in the SoA, the investigator or designee will inform the participant
of the need to use highl y effective contraception consistently  and correctly  and do cument the 
conversation and the participant ’s affirmation in the participant ’s chart ( participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception).  
In addition, the investigator or designee will inst ruct the participant to call immediately  if the 
selected contraception method is discontinued or if pregnancy  is known or suspected in the 
participant or partner.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 365.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention . A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participants to 
meet the CONSORT publishing requirements and to res pond to queries from regulatory  
authorities. Minimal information includes demography , screen failure details, eligibility  
criteria, and an y SAE s.
Primary  study  only:  Individuals who do not meet the criteria for participation in this study  
(screen failure ) may  be rescreened under a different participant number .
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention 
Administration (Primary Study)
The following conditions are temporary  or self -limiting and a participant may  be vaccinated 
once the condition(s) has/have resolved and no other exclusion criteria are met.   The booster 
study does not include temporary  delay  criteria.
1.Current febrile illness (body  temperature 
≥100.4°F [≥38.0°C]) or other acute illness 
within 48 hours b efore study  intervention administration. This includes current 
symptoms that could represent a potential COVID -19 illness (refer to Section 7.1for 
further guidance) :
New or increased cough;
New or increased shortness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
2.Receipt of an y seasonal or pandemic influenza vaccine within 14 day s, or any  other 
nonstudy  vaccine within 28 days, before study  intervention administration.
3. Anticipated receipt of any seasonal or pandemic influenza vaccine within 14 day s, or any  
other nonstudy  vaccine within 28 day s, after study  intervention administration.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 374.Receipt of short -term (<14 day s) systemic corticosteroids.  Study  intervention 
administration should be delay ed until sy stemic corticosteroid use has been discontinued 
for at least 28 d ays.  Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or 
eyes) corticosteroids are permitted.
6.STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, in the primary  study , study  intervention refers to
BNT162b2, an RNA -based vaccine for immunization against COVID
-19.  All 4 production 
lots will be administered at a 30 -µgdose and 
1 of the lots will also be administered at a 
20-µgdose,with the group names Arms 1, 2, 3, 4, and5, respectivel y . The study  will 
evaluate a 2 -dose (separated by  21days) schedule in healthy  participants 12 through 50 years 
of age.
In the booster stud y, study intervention refers to BNT162b2 and BNT162b2.B.1.351, 
RNA -based vaccines for immunization against COVID -
19.  The study  will evaluate a single 
30-µgdose administered 3 months after Dose 2 in the primary  study  to healthy  participants 
18 through 50 years of age.
6.1.Study Intervention(s) Administered
6.1.1.
Primary Study
Intervention Name BNT162b2 
(BNT162 RNA- LNP vaccine utilizing modRNA)
ArmNamea
(group of participants receiving a specific 
vaccine or no vaccine )Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Type Vaccine
Dose Form ulation modRNA
Unit Dose Strength 250 µg/0.5 mL
Dosage Level 30µg(Arms 1-4); 20µg (Arm5)
Route of Adm inistration Intramuscular injection
Use Experimental
IMP or NIMP IMP
Sourcing Provided centrally by the sponsor
Packaging and Labeling Study intervention will be provided in a single -dose glass vial. 
Each vial will be labeled as required per country requirement .
a.Arms 1, 2, and 3contain US-manufactured drug substance ; Arm4 contains EU-manufactured drug 
substance ;Arm5 contains US-manufactured drug substance from one of the US lots in the study .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 386.1.2. Booster Study
Intervention Names BNT162b2a
BNT162.B.1.351 (BNT162b2s01 )b
(BNT162 RNA -LNP vaccine utilizing modRNA)
Arm  Nam ea
(group of participants receiving a specific 
vaccine or no vaccine)Booster 1: BNT162b2
Booster 2 :BNT162.B.1.351
Type Vaccine
Dose Form ulation modRNA
Unit Dose Strength 250 µg/0.5 mL
Dosage Level 30 µg 
Route of Adm inistration Intramuscular injection
Use Experimental
IMP or NIMP IMP
Sourcing Provided centrally by the sponsor
Packaging and Labeling Study intervention will be provided in a single -dose glass 
vial.  Each vial will be labeled as required per country 
requirement.
a.Reference vaccine.
b.Vaccine with B.1.351 variant –specific mutations. Study intervention label is BNT162b2s01.
6.1.3. Administration
Primary  study :  Participants will receive 1 dose of study  intervention as randomized at each 
vaccination visit (Visits 1 and 2) separated b y 21 days in accordance with the study ’s SoA.  
Full details are described in the I P manual.
Booster stud y: Participants will receive 1 dose of study  intervention based on
rerandomiz ation at the vaccination visit (Visit 4).  Participants will b e assigned 1 vial of
either BNT162 b2(Booster 1) orBNT162b2 .B.1.351 (Booster 2) . All participants will 
receive a total dose of 30 µg.
Full details are described in the I P manual.
Study  intervention should be administered intramuscularl y into the deltoid muscle, preferabl y 
of the nondominant arm, by  an unblinded administrator.
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appro priate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of study  interventions should be performed b y an appropriately  qualified, 
GCP -trained, and vaccine- experienced member of the study  staff (eg, ph ysician, nurse, 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 39physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by  
local, state, and institutional guidance.
Study  intervention administration details will be recorded on the CRF.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study  intervention sreceived and an y discrepancies are 
reported and resolved before use of the stud y intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study intervention s
must be stored in a secure, environmentall y controlled, and monitored (manual or 
automated recording ) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.  At a minimum, daily minimum and 
maximum temperatures for all site storage locations must be documented and available 
upon request.  Data for nonworking day s must indicate the minimum and maximum 
temperature ssince previously  documented for all site storage locations upon ret urn to 
business.
3.Any excursions from the study  intervention label storage conditions should be reported to 
Pfizer upon discovery  along with an y actions taken.  The site should actively  pursue 
options for returning the study  intervention to the storage cond itions described in the 
labeling, as soon as possible.  Once an excursion is identified, the study  intervention must 
be quarantined and not used until Pfizer provides permission to use the study  
intervention.  Specific details regarding the definition of a n excursion and information the 
site should report for each excursion will be provided to the site in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded by  the storage conditions 
stated on the label.
5.Study  interventions should be stored in their original containers.
6.See the IP manual for storage conditions of the study  intervention.
7. The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconcili ation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records) , such as the IPAL or 
sponsor -approved equivalent . All study  intervention swill be accounted for using a study  
intervention accountability  form/record.
8.Further guida nce and information for the final disposition of unused study  interventions 
are provided in the I P manual. All destruction must be adequatel y documented.  If 
destruction is authorized to take place at the investigator site, the investigator must ensure 
that the materials are destroyed in compliance with applicable environmental regulations, 
institutional policy , and any  special instructions provided by  Pfizer.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 40Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery as described in the I P manual.
6.2.1. Preparation and Dispensing
See the IP manual for detailed instructions on how to prepare the study  intervention for 
administration.  Study  intervention should be prepared and dispensed by  an appropriatel y 
qualified and experienced member of the stud y staff (eg, ph ysician, nurse, phy sician’s 
assistant, nurse prac titioner, pharmacy  assistant/technician, or pharmacist) as allowed by  
local, state, and institutional guidance.  A second staff member will verify  the preparation 
and dispensing.
Study  intervention will be prepared by  qualified unblinded site personnel acc ording to the IP 
manual.  The stud y intervention will be administered in such a way  to ensure the participants 
remain blinded.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation (randomization) of participants to vaccine groups will proceed through the use of 
an IRT s ystem (I WR).  The site personnel (study  coordinator or specified designee) will be 
required to enter or select information including but not limited to the user’s I D and 
password, the protocol number, and the participant number.  The site personnel will then be 
provided with a vaccine assignment and randomization number.  The IRT system will 
provide a confirmation report containing the participant number, randomization number, and 
study  intervention allocation assigned.  The confirmation report must be stored in the site’s 
files.
The study -specific I RT reference manual and I P manual will provide the contact information 
and further details on the use of the IRT s ystem.
6.3.2. Blinding of Site Personnel
Primary  study :  Because the volumes of the 20
-µg and the 30 -µg doses of the investigational 
vaccine are different, this study  is observer -blinded, which requires the study  staff receiving, 
storing, dispensing, preparing, and administering the study  interve ntions tobe unblinded.
Booster stud y:  To align with the primary  study , this study  is observer -blinded, which 
requires the stud y staff receiving, storing, dispensing, preparing, and administering the stud y 
interventions to be unblinded.
All other study  and site personnel, including the investigator, investigator staff, and 
participants, will be blinded to study
 intervention assignments.  In particular, the individuals 
who evaluate participant safet y will be blinded.
The responsibility  of the unblinded disp enser and administrator must be assigned to an 
individual or individuals who will not participate in the evaluation of an y study  participants.  

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 41Contact between the unblinded dispenser and study participants and unblinded administrator 
and study  participant s should be kept to a minimum.  The remaining site personnel must not 
know study  intervention assignments.
In the event of a Qualit y Assurance audit, the auditor(s) will be allowed access to unblinded 
study  intervention records at the site(s) to verify  that randomization/dispensing has been done 
accuratel y.
6.3.3. Blinding of the Sponsor
The majority of sponsor staff will be blinded to study  intervention allocation.  The blinded 
study  team will become unblinded to the primary  study randomization information at the 
time of the database release of the primary  study . These same stud y team members will 
remain blinded to the randomization information for the booster stud y until completion of 
that phase.
All laboratory  testing personnel performing serology  assay s will remain blinded to study  
intervention assigned/received throughout the testing for the primary  study and for the 
booster study , respectively .  The following sponsor staff, who will have no part in the blinded 
conduct of t he stud y, will be unblinded (further details will be provided in a data blinding 
plan):
Those study  team members who are involved in ensuring that protocol requirements for 
study  intervention preparation, handling, allocation, and administration are fulfil led at the 
site will be unblinded for the duration of the stud y (eg, unblinded study manager, 
unblinded clinical research associate).
Unblinded clinician(s) who are not direct members of the study  team and will not 
participate in an y other study -related ac tivities will review unblinded protocol deviations.
6.3.4. Breaking the Blind
All study  participants will receive BNT162b2 ;
blinding refers onl y to which vaccine lot or 
vaccine dose (primary  study ) or to which vaccine (booster study ) the participant will receive.  
The I RT will be programmed with blind -breaking instructions.  I n case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s study  
intervention assignment is warranted.  Participant safet y must alwa ys be the first 
consideration in making such a determination.  If the investigator decides that unblinding is 
warranted, the investigator should make every  effort to contact the sponsor prior to 
unblinding a participant’s vaccine assignment unless this could delay  further management of 
the participant.  If a participant’s vaccine assignment is unblinded, the sponsor must be 
notified within 24 hours after breaking the blind.  The date and reason that the blind was 
broken must be recorded in the source docume ntation and CRF.
The study -specific I RT reference manual and I P manual will provide the contact information 
and further details on the use of the IRT s ystem.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 426.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.  
The dose of stud y intervention and study particip ant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention.
6.5. Concomitant Therapy
The following concomitant medications and vaccinations will be recorded in the CR F:
All vaccinations received from 28 day s prior to study  enrollment until the 1-month 
follow -up visit (Visit 3 ,
primary  study/Visit 6 , booster study).
Prohibited vaccines and medications listed in Section 6.5.1 will be recorded, to include 
start and stop dates, name of the medication, dose, unit, route, and frequency .
6.5.1. Prohibited During the Study
Receipt of the following vaccines and medications during the time periods listed below may  
exclude a participant from the per
-protocol anal ysis from that point onwards and , in the 
primary  study ,may require vaccinations to be discontinued in that participant; however, it is 
anticipated that the participant wou ld not be withdrawn from the study  (see Section 7).  
Medications should not be withheld if required for a participant’s medical care.
Unless considered medically  necessary , no vaccines other than study  intervention should 
be administered with in 28 day s before and 28 days after each study  vaccination.  One 
exception to this is that seasonal and pandemic influenza vaccine can be given at least 
14days after, or at least 14 day s prior to, the administration of study  intervention.
Receipt of chronic sy stemic treatment with known immunosuppressant medications, or 
radiotherap y, within 60 days before enrollment through conclusion of the study.
Receipt of s ystemic corticosteroids ( ≥20 mg/day  of prednisone or equivalent) for 
≥14days is prohibited from 28 day s prior to enrollment to Visit 3 , primary  s tudy/Visit 6 ,
booster s tudy.
Receipt of blood/plasma products or immunoglobulins within 60 day s before enrollment 
through conclusion of the study .
Receipt of an y other (nonstudy ) coronavirus vaccine at an y time prior to or during study  
participation is prohibited.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 43Receipt of proph ylactic medications intended to prevent s ymptoms associated with 
COVID -19.  However, if a participant is taking a medication for another condition, even 
if it may  have such properti es, it should not be withheld prior to study  vaccination.
Prophy lactic antipy retics and other pain medication to prevent s ymptoms associated with 
study  intervention administration are not permitted.  However, if a participant is taking a 
medication for another condition, even if it may  have antipy retic or pain -relieving 
properties, it should not be withheld prior to study vaccination.
6.5.2. Permitted During the Study
The use of antip yretics and other pain medication to treat symptoms associated with study  
interve ntion administration or ongoing conditions is permitted.
Medication other than that described as prohibited in Section 6.5.1 required for treatment of 
preexisting stable conditions is permitted.
Inhaled, topical, or localized injections of corticosteroids (eg, intra -articular or intrabursal 
administration) are permi tted.
6.6. Dose Modification
Not applicable for this study .
6.7.Intervention After the End of the Study (Primary Study)
If the 20- µg dose group (Arm 5) is found to have a suboptimal immune response, as 
determined b y the sponsor, this group will be offered a single 30-µg dose outside of the 
study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention (Primary Study )
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation) . Reasons for definitive discontinuation of study  
intervention include the following :AEs; participant request; investigator request; pregnancy ; 
protocol deviation (including no longer meeting all the inclusi on criteria, or meeting 1 or 
more exclusion criteria *). In general, unless the investigator considers it unsafe to administer 
the second dose, or the participant does not wish to receive it, it is preferred that the second 
dose be administered.
*
Apositi ve SARS -CoV -2 NAAT result without symptoms or a COVID -19 diagnosis 
(signs/s ymptoms onl y or signs/sy mptoms and a positive SARS -CoV -2 NAAT result) should 
not result in discontinuation of study  intervention.  If study intervention (Dose 2) has been 
delay ed pe r Section 5.5, because of febrile or other acute illness ( Item 1 in the list in 
Secti on 5.5), and the investigator later diagnoses the signs and s ymptoms as COVID -19 (with 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 44or without a positive SARS -CoV -2 NAAT result), the participant should not be discontinued 
from anyfurther doses of study  intervention.
Note that discontinuation of study  intervention does not represent withdrawal from the stud y.
Per the study  estimands, i f study  intervention is definitively  discontinued, the participant will 
remain in the study  to be evaluated for safet y and immunogenicit y
.See the SoA for data to 
be collected at the time of discontinuation of study intervention and follow -up for an y furth er 
evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, post vaccination study  follow -up, 
and/or future collection of additional information.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request.  Reasons for 
discont inuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  sponsor ;
AEs;
Participant request; 
Investigator request;
Protocol deviation
.
If a participant does not return for a scheduled visit, every  effort should be made to contact 
the participant.  All attempts to contact the participant and information received during 
contact attempts must be documented in the participant’s source document.  I n any  
circumstance, every  effort should be made to document participant outcome, if possible.
The investigator or his or her designee should capture the reason for withdrawal in the CRF 
for all participants.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, andthe investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 45If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use any  data
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawal of Consent
Participants wh o request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by  the participant to provide this 
information.  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow -up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  the investigator, as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or post vaccination study  follow -up, and entered on the appropriate CRF page.  In the 
event that vital status (whether the participant is alive or dead) is being measured, publicl y 
available information should be used to determine vital status only  as appropriately  directed 
in accordance with local law.
7.3.Lost to 
Follow-up
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertai n whether or not the participant wishes to and/or 
should continue in the study ;
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 468.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.
The full date of birth will be collected to criticall y evaluate the immune response and safet y 
profile b y age.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be di scussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all particip ants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to tim e there may be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participant s in the primary  study  is 
approximately  20mLfor participants 12 through 15 years and 40mLfor participants 
≥16yearsof age .  The total blood sampling volume for individual participants in the booster 
study  is approximately  150 mL for each participant.  
Additional blood samples may be taken 
for safety  assessments at times specified by  Pfizer, provided the total volume taken during 
the study  does not exceed 550 mL during an y period of 60 consecut ive day s.
8.1.Immunogenicity Assessments
Serum samples will be obtained for immunogenicity  testing at the visits specified in the SoA. 
The test sto be performed will be the full-length S- binding IgG-concentration assay and 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 47measurement of SARS -CoV -2 neutralizing titers .  For the primary  study, full-length 
S
-binding IgG concentrations will be measured for the lot -comparison anal yses on all eligible 
samples. Testing for SARS- CoV -2 reference -strain neutralizin g titers will be performed on 
all eligible samples for the dose -comparison anal ysis.  For the booster s tudy,testing for both 
SARS -CoV -2 reference -strain and B.1.351 -strain 
neutralizing titers and full -length S -binding 
IgG concentrations will be performed on all eligible samples .  Note that all immunogenicit y 
analyses will be based upon samples anal yzed at the central laboratory .
Nasal (m idturbinate )swab s at the visits specified in the SoA will be obtained as one of the 
determinations for participan ts to be included in the evaluable immunogenicity  anal ysis.  
These samples will be tested at thecentral laboratory  using a nRT-PCR test (Cepheid , an
NAAT ; FDA approved under EUA) to detect SARS -CoV -2.  Another determination for 
participants to be included in the evaluable immunogenicity  anal ysis is the N -binding 
antibody  assay .  Blood samples will be taken at visits specified in the SoA and anal yzed at 
the central laboratory .  A positive result 
oneither test will result in the immun ogenicity  data 
from that participant being excluded from the evaluable portion of the study population.  
However, a dmin istration of study  interv ention is not dependent on these test results , which 
will only  be available after the study  has ended.
8.1.1. Biological Samples
Blood and nasal swab samples will be used only  for scientific research.  Each sample will be 
labeled with a code so that the laboratory  personnel testing the samples will not know the 
participant’s identity .  Samples that remain after pe rforming assay s outlined in the protocol 
may be stored by  Pfizer.  Unless a time limitation is required by  local regulations or ethical 
requirements, the samples will be stored for up to 15 y ears after the end of the study  and then 
destroy ed.  If allowed b y the ICD, stored samples may  be used for additional testing to better 
understand the immune responses to the vaccine (s) under study  in this protocol, to inform the 
development of other products, and/or for vaccine- related assay  work supporting vaccine 
programs.  No testing of the participant’s DNA will be performed.
The participant may request that his or her samples, if still identifiable, be destroy ed at any  
time; however, an y data alread y collected from those samples will still be used for this 
research .  The biological samples may  be shared with other researchers as long as 
confidentiality  is maintained and no testing of the participant’s DNA is performed .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
A clinical assessment, including medical history , will be performed on all participants at their
first visit t o establish a baseline.  Significant medical history and observations from an y 
physical examination, if performed, will be documented in the CRF.
AEs and SAEs are collected, recorded, and reported as defined in Section 8.3.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 48Acute reactions within the first 30 minutes will be assessed and documented in the AE CRF.
The safet y parameters also include reactogenicit y e-diary  reports of local reactions ,systemic 
events (including fever), and use of antip yretic medication that occur in the 7 day s after 
administration of the study  intervention.  These prospectivel y self -collected occurrences of 
local reactions and s ystemic events are graded as d escribed in Section 8.2.2 .
8.2.1. Clinical Safety Laboratory Assessments
Clinical safety  laboratory assessments will not be collected in this study .
See Section 10.5 , Appendix 5, for suggested actions and follow -up assessments in the event 
of potential DILI .
8.2.2. Electronic Diary
Participants will be required to complete a reactogenicity  e-diary  through an application 
installed on a provisioned device or on the participant’s own personal device.  All 
participants will be asked to monitor and record local reactions, sy stemic events, and 
antipy retic medication usage for 7 days from the day  of administration of the study  
intervention.  The reactogenicity  e-diary  allows recording of these assessments only  within a 
fixed time window, thus providing the accurate representation of the par ticipant’s experience 
at that time.  Data on local reactions and systemic events reported in the reactogenicit y 
e-diary  will be transferred electronically  to a third- party vendor, where they will be available 
for review b y investigators and the Pfizer clin icians at all times via an internet -based portal.
At intervals agreed to b y the vendor and Pfizer, these data will be transferred electronicall y 
into Pfizer's database for anal ysis and reporting.  Generally , these data do not need to be 
reported b y the inv estigator in the CRF as AEs.
Investigators (or designee) will be required to review the reactogenicity  e-diary  data online at 
frequent intervals as part of the ongoing safet y review.
The investigator or designee must obtain stop dates from the participant for any  ongoing 
local reactions, sy stemic events, or use of antipyretic medication on the last day  that the 
reactogenicity  e-diary  was completed.  The stop dates should be documented in the source 
documents and the information entered in the CRF.
8.2.2.1. Grading S cales
The grading scales used in this study  to assess local reactions and systemic events as 
described below are derived from the FDA CBER guidelines on toxicity  grading scales for 
healthy  adult volunteers enrolled in preventive vaccine clinical trials.12
8.2.2.2. Local Reactions
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
redness, swelling, and pain at the injection site and to record the s ymptoms in the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 49reactogenicity  e-diary .  If a local reaction persists bey ond the end of the reactog enicity  
e-diary  period following vaccination, the participant will be requested to report that 
information.  The investigator will enter this additional information in the CRF.
Redness and swelling will be measured and recorded in measuring device units 
(range: 1to21) and then categorized during anal ysis as absent, mild, moderate, or severe 
based on the grading scale in Table 1.  Measuring device unit s can be converted to 
centimeters according to the following formula: 1 measuring device unit = 0.5 cm.  Pain at 
the injection site will be assessed b y the participant as absent, mild, moderate, or severe 
according the grading scale in Table 1.
If a Grade 3 local reaction is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to classify  a 
participant’s local reaction as Grade
4.  If a participant experiences a confirmed Grade 4 local 
reaction, the investigator must immediately  notify  thesponsor and, if it is determined to be 
related to the administration of the study  intervention, further vaccinations will be 
discontinued in that participant.
Table 1. Local Reaction Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Pain at the 
injection siteDoes not interfere 
with activityInterferes with activity Prevents daily 
activityEmergency room visit 
or hospitalization for 
severe pain
Redness >2.0 cm to 5.0 cm 
(5 to 10measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(≥21measuring 
device units)Necrosis or exfoliative 
dermatitis
Swelling >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(≥21measuring 
device units)Necrosis
8.2.2.3. Systemic Events
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain, and new or 
worsened joint pain and to record the s ymptoms in the reactogenicit y e-diary .  The symptoms 
will be assessed b y the participant as absent, mild, moderate, or severe according to the 
grading scale in Table 2.
If a Grade 3 s ystemic event is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to classify  a 
participant ’s systemic event as Grade 4.  If a participant experiences a confirmed Grade 4 
systemic event, the investigator must immediately notify  the sponsor and, if it is determined 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 50to be related to the administration of the study  intervention, further vaccination s will be 
discontinued in that participant.
Table 2. Systemic Event Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening 
(Grade 4)
Vom iting 1-2 times in 
24hours>2 times in 
24hoursRequires IV 
hydrationEmergency room visit 
or hospitalization for 
hypotensive shock
Diarrhea 2 to 3 loose stools 
in 24 hours4 to 5 loose stools 
in 24 hours6 or more loose stools 
in 24 hoursEmergency room visit 
or hospitalization for 
severe diarrhea
Headache Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe headache
Fatigue/tiredness Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe fatigue
Chills Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe chills
New or w orsened 
muscle painDoes not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe ne w or worsened 
muscle pain
New  or w orsened 
joint painDoes not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization for 
severe ne w or worsened 
joint pain
Abbreviation: IV = intravenous.
During the 7 days following each vaccination, potential COVID -19 symptoms that overlap 
with solicited sy stemic events (ie, fever, chills, new or increased muscle pain, diarrhea, 
vomiting) should be assessed by  the investigator.
If, in the investigator’s opinion, the sy mptoms are considered more likely  to be vaccine 
reactogenicity , but a participant is required to demonstrate that they  are SARS -CoV -2–
negative, a local SARS
-CoV -2 test may  be performed: if positive, the sy mptoms should be 
recorded as an AE rather than as sy stemic events in the reactogenicit y e-diary .
8.2.2.4. Fever
In order to record information on fever, a thermometer will be given to participants with 
instructions on how to measure oral temperature at home.  Temperature will be collected in 
the reactogenicit y e-diary in the evening dail y during the reactogenicit y e-diary  reporting 
period.  It will also be collected at an y time during the reactogenicit y e-diary  data collection 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 51periods when fever is suspected.  Fever is defined as an oral temperature of ≥38.0°C 
(100.4°F).  The highest temperature for each day  will be recorded in the reactogenicit y 
e-diary .  Temperature will be measured and recorded to 1 decimal place. Temperatures 
recorded in degrees Fahrenheit will be programmatically  converted to degrees Celsius and 
then categorized according to the scale shown in Table 3during analy sis
.
If a fever of ≥39.0°C (102.1°F) is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to confirm a 
participant’s fever as >40.0°C (>104.0°F).  If a participant experiences a confirmed fever 
>40.0°C (>104.0°F), the investigator must immediately  notify  the sponsor and, if it is 
determined to be related to the administration of the study  intervention, further vaccinations 
will be discontinued in that participant.
Table 3. Scale for Fever
≥38.0-38.4°C (100.4 -101.1°F)
>38.4 -38.9°C (101.2 -102.0°F)
>38.9 -40.0°C (102.1 -104.0°F)
>40.0°C (>104.0°F)
8.2.2.5. Antipyretic /Analgesic Medication
The use of antip yretic/analgesic medication to treat sy mptoms associated with study  
intervention administration will be recorded in the reactogenicit y e-diary  daily  during the 
reporting period (Day  1 through Day 7).
8.2.3. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity
 of at least 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the SoA , 
immediately  before the administration of each vaccine dose.  A negative pregnancy  test result 
will be require d prior to the participant’s receiving the study  intervention .  Pregnancy  tests 
may also be repeated if requested by  IRBs/ECs or if required b y local regulations.  I n the 
case of a positive confirmed pregnancy , the participant will be withdrawn from 
admini stration of study  intervention but may  remain in the study .
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's parent(s)/legal guardian ).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 52The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain respon sible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1).
Each participant
/parent(s)/legal guardian will be questioned about the occurrence of AEs in a 
nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain spe cific follow -up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
During the primary  study, t he time period for actively  eliciting and collecting AEs and SAEs 
(“active collection period”) for each particip antbegins from the time the 
participant /parent(s)/legal guardian provides informed consent, which is obtained before the 
participant ’s participation in the study  (ie, before undergoing any  study -related procedure 
and/or receiving study  intervention ), through and including Visit 3 (1-month follow -up).  In 
addition, any  AEs occurring up to 48hours after the blood draw and nasal swab collection at 
Visit 3 must be recorded in the CRF.
During the booster s tudy, the time period for actively  eliciting and collecting AEs and SAEs 
(“active collection period”) for each participant begins from the time the participant provides 
informed consent, which is obtained before the participant’s enrollment intothe booste r 
study at Visit 4 (ie, before undergoing an y stud y-related procedure and/or receiving study  
intervention), through and including Visit 6(1-month follow -up).  In addition, any  AEs 
occurring up to 48 hours after the blood draw and nasal swab collection at Visit 6must be 
recorded in the CRF.
Follow -up by  the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant definitively  discontinues or temporarily  discontinues study  inter vention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the Vaccine SAE Report ingForm.
Investigators are not obligated to activel y seek AE sor SAE safter the participant has 
concluded study  participation .  How ever, if the investigator learns of any  SAE, including a 
death, at an y time after a participant has completed the study , and he/she considers the event 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 53to be reasonably  related to the study  intervention, the investigator must promptly  report the 
SAE to Pfi zer using the Vaccine SAE Report ingForm .
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the Vaccine SAE Report ingForm immediatel y 
upon awareness 
and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3.The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period , 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs an
d/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety .
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 54The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.   The 
sponsor will co mply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB
s/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSAR sor other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  interventio nunder stud y during pregnancy  or br eastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing study 
intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to study  
intervention due to environmental exposure. Below are examples of environmental 
exposure during pregnancy :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  inhalation or skin contact.
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  inhalation, or skin contact then exposes his female partner prior to or 
around the time of conception
.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety  on the Vaccine SAE Report ingForm and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 55pregnancy  will be collected after the start of study  intervention and until 1 month
after the last dose of study  intervention.
If EDP occurs in the setting of environmental exposure, the invest igator must report 
information to Pfizer Safety  using the Vaccine SAE Report ingForm and EDP 
Supplemental Form. Since the exposure information does not pertain to the 
participant enrolled in the study , the information is not recorded on a CRF; however, 
a copy of the completed Vaccine SAE Report ingForm is maintained in the ISF.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the eve nt of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a conge nital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congen ital anomal y), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention.
Additional information regarding the EDP may  be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The invest igator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 56A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure durin g breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by inhalation or skin contact.
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the 
Vaccine SAE Report ingForm. When exposure 
during breastfeeding occurs in the setting of environmental exposure, the exposure 
information does not pertain to the participant enrolled in the study , so the information is not 
recorded on a CRF. However, a cop y of the completed Vaccine SAE Report ingForm is 
maintained in the ISF
.
An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact with the 
study  intervention , which may  or may  not lead to the occurrence of an AE.  Such persons 
may include healthcare providers , famil y members, and other roles that are involved in the 
trial participant’s care.
The investigator must report occupational exposure to Pfizer Safet y within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE.  The information 
must be reported using the Vaccine SAE Report ingForm.  Since the information does not 
pertain to a 
participant enrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed Vaccine SAE Report ingForm is maintained in the ISF.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
This section provides information on AESI s that may  be detected during the study :
Confirmed COVID -19 diagnosis ( clinical signs/s ymptoms and positive SARS -CoV -2 
NAAT test)

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 57Clinically  confirmed cases of MI S-C13defined as follows:
An individual <21 y ears of age presenting with fever ( ≥38.0 °Cfor ≥24 hours or 
report of subjective fever lasting ≥24 hours ), AND
Laboratory  evidence of inflammation (based on local laboratory  ranges) i ncluding, 
but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, 
procalcitonin, D
-dime r, fer ritin, LDH, or IL-6, elevated neutrophils, reduced 
lymphocy tes,and low albumin ;AND
Evidence of clinically  severe illness requiring hospitalization, with multisy stem (>2) 
organ involvement (cardiac, renal, respiratory , hematologic, gastrointestinal,
dermatologic ,or neurological); AND
No alternative plausible diagnoses; AND
Positive for current or recent SARS- CoV -2 infection by  NAAT ( RT-PCR ), serology , 
or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of 
symptoms
All AESI s must be reported as an AE or SAE following the procedures described in
Section 8.3.1 through Section 8.3.4. An AESI  is to be recorded as an AE or SAE on the 
CRF. Inaddition, an AESI  that is also an SAE must be reported using the Vaccine SAE 
Reporting Form.
8.3.8.1. Lack of Efficacy
Lack of efficacy  is re portable to Pfizer Safet y only if associated with an SAE.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the 
study  
intervention by the wrong participant , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE 
Report ingForm to Pfizer Safety 
Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 58Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study participant ;
The administration of expired study  intervention;
The administration of an incorrect study  intervention;
The administration o f an incorrect dosage;
The administration of study  intervention that has undergone temperature excursion from 
the specified storage range, unless it is determined by  the sponsor that the study  
intervention under question is acceptable for use.
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Wheth er or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE pag e of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a Vaccine SAE 
Report ingForm only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of study  intervention greater than 1 dose of study interven tion within 
a 24-hour time period will be considered an overdose.
Pfizer does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact the medical m onitor within 24 hours .
2.Closely  monitor the particip ant for an y AEs/SAEs .
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Safety  only when associated with a nSAE .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 59Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the m edical m onitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
8.7.Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.8.Biomarkers
Biomarkers are not evaluated in this study .
8.9.Immunogenicity Assessments
Immunogenicit y assessments are described in Section 8.1.
8.10. Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
8.11. Study Procedures
8.11.1.
Visit 1 – Vaccination 1 (Day 1)
Before enrollment and before an y stud y
-related procedures are performed, voluntary , written, 
study -specific informed consent will be obtained from the participant or his /her 
parent(s) /legal guardian , as appropriate .  Each signature on the ICD must be personall y dated 
by the signatory .  The investigator or his or her designee will also sign the I CD.  A copy  of 
the signed and dated ICD must be given to the participant /parent(s)/legal guardian .  The 
source data must reflect that the infor med consent was obtained before participation in the 
study .
It is anticipated that the procedures below will be conducted in a stepwise manner. The visit 
may be conducted across 2 consecutive day s; if so, all steps from assessing the inclusion and 
exclusi on criteria onwards must be conducted on the same day.
Assign a single participant number using the IRT sy stem.
Obtain the participant’s demograph y (including date of birth, sex, race, and ethnicity).  
The full date of birth will be collected to critically evaluate the immune response and 
safet y profile b y age.
Obtain an y medical history of clinical significance.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 60Perform a clinical assessment. If the clinical assessment indicates that a phy sical 
examination is necessary to comprehensivel y evaluate the part icipant, perform a phy sical 
examination and record any  findings in the source documents and, if clinically  
significant, record on the medical history  CRF.
Measure the participant’s height and weight.
Measure the participant’s body  temperature.
Perform urine pregnancy test on WOCBP as described in Section 8.2.3.
Discuss contraceptive use as described in Section 
10.4.
Record nonstud y vaccinations as described i
nSection 6.5.
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met.
Ensure that the participant meets none of the temporary  delay  criteria as described in
Section 5.5.
Collect a blood sample (approximately  20 mL for participants ≥
16years of age and 
approximately  10mL for participants 12 through 15 years of age) for immunogenicity  
testing and to test for prior COVID
-19.  Please refer to the ISFfor further instructions.
Obtain a nasal (midturbinate) swab (collected b y site staff) for determination of current 
SARS -CoV -2 status .Please refer to the ISF for further instructions.
A blinded site staff member selects the age stratum and obtains the randomization 
number using the IRT system.  An unblinded site staff member then enters the participant 
number (SSID) and randomization num ber to assign the stud y intervention allocation 
number.
Unblinded site staff member(s) will dispense/administer 1 dose of study  intervention into 
the deltoid muscle of the preferabl
y nondominant arm.  Please refer to the IP manual for 
further instruction o n this process.
Blinded site staff must observe the participant for at least 30 minutes after study  
intervention administration for an y acute reactions.  Record an y acute reactions 
(including time of onset) in the participant’s source documents and on the AE page of the 
CRF, and on an SAE form as applicable.
Explain the e -diary  technologies available for this study  (Section 8.2.2), and assist the 
participant in downloading the stud y application onto the participant’s own device or 
issue a provisioned device if required.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 61Provide instructions on reactogenicity  e-diary  completion and ask the participant to 
complete the reactogenicity  e-diary from Day 1 through Day 7, with Day 1 being the day  
of vaccination.
A
sk the participant to contact the site staff or investigator immediatel y if the participant 
experiences an y of the following from Day  1 through Day 7 after vaccination (where Day  
1 is the day  of vaccination) to determine if an unscheduled reactogenicity  visit is 
required: 
Fever ≥39.0°C (≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units) .
Severe pain at the injection site.
Any severe s ystemic event.
Issue a measuring device to measure local reactions at the injection site and a 
thermometer for recording dail
y temperatures and provide instructions on their use.
Record AEs /SAEs as described in Section 8.3.
Ask the participant to contact the site staff or investigator if a medicall y attended event 
(eg,doctor ’s visit, emergency  room visit) or hospitalization occurs.
Ask the participant to contact the site staff or investigator if he/she develops sy mptoms of 
a COVID -19 infection, as defined by  the CDC ,14including :
New or increased cough; 
New or increased short ness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
Schedule an appointment for the participant to return for the next study  visit.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 62Remind the participant to bring the reactogenicit y e-diary  to th e next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs and an unblinded 
dispenser/administrator updates the study  intervention accountability records.
The investigator or appropriately qualified designee reviews the reactogenicity  e-diary  data 
online following vaccination to evaluate participant compliance and as part of the ongoing 
safet y review.  Dail y review is optimal during the active diary  period.
8.11.2. Visit 2 – Vaccination 2 (19 to 23 Days After Visit 1 )
Record AEs /SAEs as described in Section 8.3.
Review the participant’s reactogenicity  e-diary  data.  Collect stop dates of any  
reacto genicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  was 
completed and record stop dates in the CRF if required.
Perform urine pregnancy test on WOCBP as described in Section 8.2.3.
Discuss contraceptive use as described in Section 
10.4.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an
y of the prohibited medications specifie d in Section 6.5.1 received b y 
the participant if required for his or her clinical care.
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met. If not, the participant may  not receive further study  intervention but will remain 
in the study  to be evaluated for safet y, immunogenicity , and efficacy  (see Section 7.1).
Measure the participant’s body  temperature.
Ensure that the participant meets none of the temporary  delay  criteria as described in
Section 5.5.
Unblinded site staff member(s) will dispense/administer 1 dose of study  intervention into 
the deltoid m uscle of the preferabl y nondominant arm.   Please refer to the IP manual for 
further instruction on this process.
Blinded site staff must observe the participant for at least 30 minutes after study  
intervention administration for an y acute reactions.  Recor d any acute reactions 
(including time of onset) in the participant’s source documents and on the AE page of the 
CRF, and on an SAE form as applicable.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 63Ensure the participant has a measuring device to measure local reactions at the injection 
site and a ther mometer for recording daily  temperatures.
Ensure the participant remains comfortable with the chosen e- diary  platform, confirm 
instructions on e -diary  completion, and ask the participant to complete the reactogenicity  
e-diary  from Day 1 through Day 7, with Day 1 being the day  of vaccination.
Ask the participant to contact the site staff or investigator immediatel y if the participant 
experiences an y of the following from Day 1 through Day 7 after vaccination (where Day  
1 is the day  of vaccination ) to determine if an unscheduled reactogenicity  visit is 
required: 
Fever ≥39.0°C (≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Ask the participant to contact the site staff or investigator if a medicall y attended event 
(eg,doctor’s visit, emergency  room visit) or hospitalization occurs.
Ask the participant to contact the site staff or investigator if he/she develops sy mptoms of 
a COVID -19 infection, as defined by  the CDC ,14including :
New or increased cough; 
New or increased shortness of breath;
Chills;
New or increased mus cle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
Schedule an appointment for the participant to return for the next study  visit.
Remind the participant to bring the reactogenicit y e-diary  to the next visit.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 64Complete the source documents.
The investigator or an authorized designee completes the CRFs and an unblinded 
dispenser/administrator updates the study  intervention accountability records.
The investigator or appropriately  qualified designee reviews the reactogenicity  e-diary  
data onli ne following vaccination to evaluate participant compliance and as part of the 
ongoing safet y review.  Daily review is optimal during the active diary  period.
8.11.3. Visit 3 – 1- Month Follow -up (28 to 35 Days After Visit 2)
Record AEs /SAEs as described in Section 8.3.
Review the participant’s reactogenicity  e-diary  data.  Collect stop dates of any  
reactogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  was 
completed and record stop dates in the CRF if required.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an y ofthe prohibited medications specified in Section 6.5.1 received b y 
the participant if required for his or her clinical care.
Discuss contraceptive use as described in in Section 10.4.
Collect a blood sample (approximately  20 mL for participants ≥16 y ears of age and 
approximately  10mL for participants 12 t hrough 15years of age) for immunogenicity  
testing and to test for prior COVID -19.
Obtain a nasal (midturbinate) swab (collected b y site staff) for determination of current 
SARS -CoV -2 status .
Collect the participant’s reactogenicity e-diary  or assist the participant to remove the 
study  application from his or her own personal device.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
Booster Study Procedures
8.11.4. Visit 4 – Vaccination 3 (83 to 97 Days After Visit 2)
Before vaccination and before an y stud y-related procedures are performed, voluntary , 
written, study -specific informed consent (via an ICD addendum) will be obtained from the 
participant.  Each signature on the ICD addendum must be pers onally  dated by  the signatory .  
The investigator or his or her designee will also sign the ICD addendum .  A copy  of the 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 65signed and dated ICD addendum must be given to the participant.  The source data must 
reflect that the informed consent was obtained bef ore participation in the booster study .
It is anticipated that the procedures below will be conducted in a stepwise manner.
Perform urine pregnancy test on WOCBP as described in Section 8.2.3.
Discuss contraceptive use as described in Section 10.4.
Record nonstud y
vaccinations as described in Section 6.5.
Record details of an y of the prohibited medications specified in Section 6.5.1 received b y 
the participant if required for his or her clinical care.
Measure bod y temperature .
Ensure and documen t that all of the inclusion criteria and none of the exclusion criteria 
are met.
Collect a blood sample (approximately  50 mL) for immunogenicit y testing and to test for 
prior COVID -19.  Please refer to the ISF for further instructions.
Obtain a nasal (midt
urbinate) swab (collected by  site staff) for determination of current 
SARS -CoV -2 status.  Please refer to the ISF for further instructions.
A blinded site staff member obtains the single subject ID (SSID) number and the 
participant’s randomization number from the IRT sy stem. The SSID number will not be 
used as the primary  identifier for the participant (outside of I mpala), but must be included 
in the participant’s source documents and transcribed into the CRF.   An unblinded site 
staff member then enters t
he SSI D and randomization number to assign the study  
intervention allocation number.
Unblinded site staff member(s) will dispense/administer 1 dose of study  intervention into 
the deltoid muscle of the preferabl y nondominant arm.  Please refer to the IP man ual for 
further instruction on this process.
Blinded site staff must observe the participant for at least 30 minutes after study  
intervention administration for an y acute reactions.  Record an y acute reactions 
(including time of onset) in the participant’s source documents and on the AE page of the 
CRF, and on an SAE form as applicable.
Ensure the participant remains comfortable with the chosen e- diary  platform and assist 
the participant in downloading the stud y application onto the participant’s own device or 
issue a provisioned device if required.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 66Review instructions on e -diary  completion, and ask the participant to complete the 
reactogenicity  e-diary  from Day 1 through Day  7, with Day 1 being the day of 
vaccination.
Ask the participant to contact the site staff or investigator immediatel y if the par ticipant 
experiences an y of the following from Day  1 through Day  7 after vaccination (where 
Day 1 is the day  of vaccination) to determine if an unscheduled reactogenicity  visit is 
required: 
Fever ≥39.0°C (≥102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Issue a measuring device to measure local reactions at the injection site and a 
thermometer for recording dail y temperatures and pro vide instructions on their use.
Record AEs/SAEs as described in Section 8.3.
Ask the participant to contact the site staff or investig ator if a medicall y attended event 
(eg,doctor’s visit, emergency  room visit) or hospitalization occurs.
Ask the participant to contact the site staff or investigator if he/she develops sy mptoms of 
a COVID -19 infection, as defined by  the CDC ,14including:
New or increased cough; 
New or increased shortness of breath;
Chills;
New or increased muscle pain;
New loss of taste/smell;
Sore throat;
Diarrhea;
Vomiting.
Schedule an appointmen t for the participant to return for the next study  visit.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 67Remind the participant to bring the reactogenicit y e-diary  to the next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs and an unblinded 
dispenser/ administrator updates the study  intervention accountability records.
The investigator or appropriately  qualified designee reviews the reactogenicity  e-diary  data 
online following vaccination to evaluate participant compliance and as part of the ongoing 
safety review.  Dail y review is optimal during the active diary  period.
8.11.5. Visit 5 – 1-Week Follow- up (6 to 8 Days After Visit 4)
Discuss contraceptive use as described in Section 10.4.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an y of the prohibited medications specified in Section 6.5.1 received b y 
the participant if required for his or her clinical care.
Collect a blood sample of approximately  50mL for immunogenicit y testing.
Record AEs as described in 
Section 8.3.
Ask the participant to contact the site staff or investigator if a medicall y attended event 
(eg,doctor’s visit, emergency  room visit) or hospitalization occurs.
If the participant has completed e- diary  reporting by  Visit 5, the e -diary  may be collected 
or app deleted.
Schedule an appointment for the participant to return for the next study  visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
8.11.6. Visit 6 – 1- Month Follow -up(28 to 35 Days After Visit 4)
Discuss contraceptive use as described in in Section 10.4.
Record nonstud y vaccinations as described in Section 6.5.
Record details of an y of the prohibited medications specified in Section 6.5.1 received b y 
the participant if required for his or her clinical care.
Collect a blood sample (approximately  50 mL) for immunogenicit y testing and to test for 
prior COVID -
19.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 68Obtain a nasal (midturbinate) swab (collected b y site staff) for determination of current 
SARS -CoV -2 status.
Review the participant’ s reactogenicity  e-diary  data.  Collect stop dates of any  
reactogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  was 
completed and record stop dates in the CRF if required.
Record AEs/SAEs as described in Section 8.3.
Collect the participant’s reactogenicity  e-diary  or assist the participant to remove the 
study  application from his or her own personal devic e.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
8.12. Unscheduled Visits for a Grade 3 or Suspected Grade 4 Reaction
If a Grade 3 local reaction ( Section 8.2.2.2), s ystemic event ( Section 8.2.2.3 ), or fever 
(Section 8.2.2.4) is reported in the reactogenicit y e-diary, a telephone contact should occur to 
ascertain further details and determine whether a site visit is clinically  indicated. If a 
suspected Grade 4 local reaction ( Section 8.2.2.2), sy stemic event ( Section 8.2.2.3), or fever 
(Section 8.2.2.4) is reported in the reactogenicit y e-diary , a telephone contact or site visit 
should occur to confirm whether the event meets the criteria for Grade 4 .
A site visit must be scheduled as soon as possible to assess the participant unless any  of 
the following is true:
The participant is unable to attend the unscheduled visit.
The local reaction/s ystemic event is no longer present at the time of the telepho ne 
contact.
The participant recorded an incorrect value in the reactogenicity  e-diary  (confirmation of 
a reactogenicit y e-diary  data entry  error).
The PI  or authorized designee determined it was not needed.
This telephone contact will be recorded in the participant’s source documentation and the 
CRF.
If the participant is unable to attend the unscheduled visit, or the PI  or authorized 
designee determined it was not needed, any
 ongoing local reactions/sy stemic events must 
be assessed at the next study  visit.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 69During the unscheduled visit, the reactions should be assessed b y the investigator or a 
medically  qualified member of the study  staff such as a study  physician or a study  nurse, 
as applicable to the investigator’s local practice, who will:
Measure bod y temperature (°F/°C).
Measure minimum and maximum diameters of redness (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain (if present) in accordance with th e grades provided in 
Section
8.2.2.2 .
Assess sy stemic events (if present) in accordance with the grades provided in 
Section 8.2.2.3.
Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
The invest igator or an authorized designee will complete the unscheduled visit assessment 
page of the CRF.
9.STATISTICAL CONSIDERATIONS
Methodology
 for summary  and statistical anal yses of the data collected in this study  is 
describ ed here and further detailed in a SAP , which will be maintained by  the sponsor.  The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Estima nds and Statistical Hypotheses
9.1.1. Estimands
The estimand scorresponding to each primary  andsecondary  objective are described in the 
table sinSection 3.
The estimands to evaluate the immunogenicity  objectives are based on theevaluable 
immunogenicit ypopulation (Section 9.3). These estimands estimate the vaccine effect in the 
hypothetical settings where participants follow the study  schedules and protocol requirements 
as directed. The estimands address the objective of estimating the maximum potential 
difference between 2 groups, since the impact of noncompliance is likely  to diminish the 
observed difference between the 2 groups. Missing antibody  results will not be imputed. 
Immunogenicit y results that ar e below the LLOQ will be set to 0.5 × LLOQ in the anal ysis; 
this may  be adjusted once additional data on the assay  characteristics become available.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 70In the primary  safet y objective evaluations, missing reactogenicity e -diary data will not be 
imputed. Miss ing AE start dates will be imputed according to Pfizer safet y rules. No other 
missing information will be imputed in the safet y analysis.
9.1.2. Statistical Hypothesis
Primary Study
There are 
2primary  immunogenicity  objectives on manufacturing lot comparisons. The first
primary  immunogenicity  objective is to assess the similarity of the immune response induced 
by BNT162b2 30 µg across the 3 US lots. The null hy pothesis (H 01) is
H01: |ln(µ 1)
-ln(µ 2)| ≥ln(1.5) or|ln(µ 1) -ln(µ 3)| ≥ln(1.5) or|ln(µ 2) -ln(µ 3)| ≥ln(1.5)
where ln ( 1.5) corresponds to a 1.5 -fold equivalence margin, andln(µ 1), ln(µ 2),and ln(µ 3) are 
the natural log of the geometric mean of full-length S- binding IgG levels measured 1 month 
after Dose 2 from participants receiving BNT162b2 30 µg from the US lots in Arm 1, Arm 2,
and Arm 3, respectivel y.
Twolots will be 
consider ed similar if the 2- sided 95% CI  for the GMR is contained in the 
interval (0.67, 1.5).  The 3 lots will be considered similar if the 1.5- fold equivalence criterion 
ismet for all 3 between -lot comparisons ( Arm 1to Arm 2, Arm 1to Arm 3, and Arm 2to 
Arm 3).
The second prim ary immunogenicity  objective is to assess the similarity  of the immune 
response induced b y BNT162b2 30 µg in the EU lot to the US lots. The null hypothesis 
(H02) is
H02: |ln(µ 4)
-ln(µ p)| ≥ln(1.5) 
where ln ( 1.5) corresponds to a 1.5 -fold equivalence margin, and ln(µ 4) and ln(µ p) are the 
natural log of the geometric mean of full-
length S- binding IgG levels measured 1 month after 
Dose 2 fro m participants receiving the BNT162b2 30 µg from the EU lot and the 3 pooled 
US lots, respectively .
The EU lot and the US lots will be considered similar if the 2 -sided 95% CI for the GMR is 
contained in the interval (0.67, 1.5).
The primary  immunogenicity  objective on dose comparison is to assess the noninferiority  of 
immune response of 20 µgto the sta ndard 30- µg dose (prepared from the same lot) .  The null 
hypothesis is
H03: ln(µ 20)-ln(µ 30) ≤ln(0.67) 
where ln (0.67) 
corresponds to a 1.5-fold noninferiority  margin and ln(µ 20) and ln(µ 30) are the 
natural log of the geometri c
mean of the SARS -CoV -2 neutralizing titers measured 1month

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 73Booster Study
The study  size in each vaccine group is not based on any  formal hy pothesis test for any  
endpoint. All statistical anal yses will be descriptive.
The primary  safet y objectives include the endpoints for AEs reported within 1 month after 
vaccination. With 30 participants in each vaccine group, if the true AE rate is 1%, the 
probability  of observing at least 1 AE is 
26% ( Table 5).
Table 5
.Probability of Observin g anEvent Given a Specified Incidence 
Rate With 30 Participants per Group
True Rate of an AE Probability of Observing at Least 1 AE
0.5% 14.0%
1% 26.0%
2% 45.5%
4% 70.6%
5% 78.5%
10% 95.8%
9.3.Analysis Sets
Primary Study
For purposes of analy sis, the following anal ysis sets are defined:
Participant
Analysis SetDescription
Enrolled All participants who have a signed ICD.
Randomized All participants who are assigned a randomization number in the IRT
system.
Evaluable 
immunogenicit yAll eligible randomized participants who receive 2 doses of the vaccine 
to which they  are randomized with Dose 2 received within the 
predefined window, have at least 1 valid and determinate 
immunogenicity result from the blood sample collected within an 
appropriate window at 1 month after the Dose 2 visit, are negative for 
SARS -CoV -2 infection during the stud y, and have no other important 
protocol deviations as determined by  the clinician.
All-available 
immunogenicit yAll participants who receive at least 1 dose of the study  intervention 
with at least 1 valid and determinate immunogenicity  result after 
vaccination.
Safety All randomized participants who receive at least 1 dose of the stud y 
intervention.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 74Booster Study
For purposes of analy sis, the following anal ysis sets are defined:
Participant 
Analysis SetDescription
Enrolled All participants who have a signed ICD at Visit 4.
Randomized All participants who are assigned a randomization number at Visit 4 in 
the IRTsystem.
Booster evaluable 
immunogenicit yAll eligible randomized participants who receive 2 doses of the vaccine 
to which they  are randomized in the primary  study with Dose 2 
received within the predefined window, receive Dose 3 
to which they  
are randomized in the booster s tudy with Dose 3 received within the 
predefined window, have at least 1 valid and determinate 
immunogenicit
y result from the blood sample collected within an 
appropriate window at 1 month after the Dose 3 visit, are negative for 
SARS -CoV -2 infection during the primary  and booster studies, and 
have no other important protocol deviations as determined by  the 
clinician.
Booster 
all-available 
immunogenicit yAll participants who receive D ose3with at least 1 valid and 
determinate immunogenicity  result after Dose 3 .
Safety All randomized participants who receive Dose 3 .
9.4. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.  
This section is a summary of the planned statistical analyses of the primary  and secondary  
endpoints.
9.4.1. General C onsiderations
Unless stated otherwise, “vaccine group” in this section refers to participants receiving any 
1of the three 30-µg US lots ,the (30- µg)EU lot ,or the 20- µgdose group for the primary  
study  and to participants receiving BNT162b2 at 30 µg or BNT162b2 .B.1.351 at 30 µg (refer 
to Section 4.1). CIs for all endpoints in the statistical anal ysis will be presented as 2- sided at 
the 95% level unless specified otherwise.
For all the immunogenicity  endpoints, the analy sis will be based on the evaluable 
immunogenicit y population. An additional anal ysis will be performed based on the 
all-available immunogenicity  population if there is a large enough difference in sample size 
between the all -available immunogenicit y population and the eva luable immunogenicit y 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 75population.  Participants will be summarized according to the vaccine group to which they  
were randomized.
The safet y analyses will be based on the safet y population.  Participants will be summarized 
by vaccine group according to the investigational products they  actually  received.
9.4.1.1. Analyses for Binary Data
Descriptive statistics for categorical variables (eg, p roportions) are the percentage (%), the 
numerator (n) and the denominator (N) used in the percentage calculation, and the 95% CIs 
where applicable.
The exact 95% CI for binary  endpoints for each group will be computed using the 
Fdistribution (Clopper -Pearson).
9.4.1.2. Analyses for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
standard deviation, minimum, and maximum.
9.4.1.2.1. Geometric Mean Ratios
Model -Based
As the primary  approach, the GMR and associated 95% CI  will be calculated by 
exponentiating the difference in LS means and the corresponding CI s based on analysis of 
logarithmicall y transformed assay  results using a linear regression model.
Unadjusted
The GMR swill be calculated as the mean of the difference of logarithmically  transformed 
assay  results between 2 vaccine groups and exponentiating the mean.  Two -sided CI s will be 
obtained by  calculating CI s using Student’s t -distribution for the mean difference of the 
logarithmicall y transf ormed assay  results and exponentiating the confidence limits.
9.4.1.2.2. Geometric Means
The geometric means will be calculated as the mean of the assay  results after making the 
logarithm transformation and then exponentiating the mean to express results on the origi nal 
scale.  Two -sided 95% CIs will be obtained by  taking log transforms of assay  results, 
calculating the 95% CI with reference to Student’s t-distribution, and then exponentiating the 
confidence limits.
9.4.1.2.3. Geometric Mean Fold Rises
GMFRs are defined as ratio s of the results at a later time point to the results at an earlier time 
point .  GMFRs are limited to participants with nonmissing values at both time points.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 76GMFRs will be calculated as the mean of the difference of logarithmicall y transformed assay  
resul ts (later time point minus earlier time point) and exponentiating the mean.  The 
associated 2- sided 95% CI s will be obtained b y constructing CIs using Student’s 
t
-distribution for the mean difference on the logarithm scale and exponentiating the 
confidence limits.
9.4.1.2.4. Reverse Cumulative Distribution Curves
Empirical RCDCs will plot proportions of participants with values equal to or exceeding a 
specified assay  value versus the indicated assay  value, for all observed assay  values.  Data 
points will be joined by  a step function with data points on the left side of the step.
9.4.2. Primary Endpoint(s)
Primary Study
Endpoint Statistical Analysis Methods
Immunogenicit y GMRs of full-length S -binding IgG levels between the US lots
For full-length S- binding levels , the GMRs for each between -lot 
comparison ( Arm 1/Arm 2, Arm 1/Arm 3, and Arm 2/Arm 3) at 
1month after Dose 2 will be provided along with associated 2 -sided 
95% CI s (see Section 9.4.1.2.1 ).
Using a 1.5 -fold equivalence margin, 2lotswill be conside redsimilar if 
the 2-sided 95% CI for each GMR is contained in the interval 
(0.67, 1.5).
GMR of full-length S -binding IgG levels between the EU lot and 
the 3 US lots
The GMR of the EU lot (Arm 4)to the pooled US lots (Arm 4/pooled 
Arms 1, 2, and 3) at 1 month after Dose 2 will be provided along with 
associated 2- sided 95% CI s (see Section 9.4.1.2.1 ).
Using a 1.5 -fold equivalence margin, theEU lot Arm 4)andthe 
pooled 
US lot s (Arms 1-3) will be conside red similar if the 2 -sided 95% CI for 
the GMR is contained in the interval (0.67, 1.5).

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 77Endpoint Statistical Analysis Methods
GMR of SARS -CoV-2 neutralizing titers between the 20-µg dose
and the corresponding 30-µg dose
The GMR of the 20-µg dose (Arm 5) to the corresponding 30- µg dose 
(Arm 1,
2,or 3) ( 20 µg/30µg) at 1 month after Dose 2 will be provided 
along with associated 2 -sided 95% CI s (see Section 9.4.1.2.1).
Using a 1.5 -fold 
noninferiority margin, noninferiori ty ofthe 20- µg dose
(Arm 5) to the corresponding 30- µg dose (Arm 1, 2,or 3) will be 
declared if the lower limit of the 2-sided 95% CI for the GMR is > 0.67.
As the pr imary  approach for these similarity  and noninferiority
assessments, a linear regression model that includes a term for age and 
vaccine group will be used to calculate the adjusted GMR and 2 -sided 
95% CI .  The unadjusted GMR and CI  will also be calculated.
Safety Descriptive statistics will be provided for each reactogenicity  endpoint 
for each dose and vaccine group.  Local reactions and systemic events 
from Day  1 through Day  7 after each vaccination will be presented b y 
severit y and cumulatively  across severit y levels.  Descriptive summary  
statistics will include counts and percentages of participants with the 
indicated endpoint and the associated Clopper-Pearson 95% CI s (see 
Section 9.4.1.1).
AEs and SAEs will be categorized according to MedDRA terms.  
Counts, percentages, and the associated Clopper -
Pearson 95% CIs of 
AEs and SAEs from Dose 1 to 1 month after Dose 2 will be provided 
for each vac cine group.
Booster Study
Endpoint Statistical Analysis Methods
Immunogenicit y GMCs of full -length S -binding IgG levels
For full -length S- binding IgG levels, GMCs and 2 -sided 95% CIs will 
be provided for each vaccine group at baseline (before Dose 1),
1month after Dose 2 , before Dose 3, and1 week after and 1 month 
after Dose 3.
Statistical methods are described in Section 9.4.1.2.2 .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 78Endpoint Statistical Analysis Methods
GMFRs of full-length S -binding IgG levels
For full -length S- binding IgG levels, the GMFRs and 2 -sided 95% CIs 
will be provided for each vaccine group from 1 month after Dose 2 to 
1week after and 1 month after Dose 3 and from before Dose 3 to 
1week after and 1 month after Dose 3 .
GMFRs will be limited to participants with nonmissing values at both 
time point s being considered .  The statistical methods are described in 
Section 9.4.1.2.3 .
GMTs of SARS -CoV -2 reference -strain neutralizing titers and 
SARS -CoV -2 B.1.351 -strain neutralizing titers
For SARS -CoV -
2 neutralizing titers, GMTs and 2- sided 95% CI s will 
be provided for each vaccine group at baseline (before Dose 1),
1month after Dose 2 , before Dose 3, and 1 week after and 1 month 
after Dose 3.
Statistical methods are described in Section 9.4.1.2.2 .
GMFRs of SARS -CoV -2 reference -strain neutralizing titers and 
SARS -CoV -
2 B.1.351 -strain neutralizing titers
For SARS -CoV -2 neutralizing titers, the GMFRs and 2 -sided 95% CIs 
will be provided for each vaccine group from 1month after Dose 2 to 
1week after and 1 month after Dose 3 and from before Dose 3 to 
1week after and 1 
month after Dose 3 .
GMFRs will be limi ted to participants with nonmissing values at both 
time points being considered .  The statistical methods are described in 
Section 9.4.1.2.3.
Percentage of participants with 
seroresponse *to the SARS -CoV -2
reference strain and SARS -CoV -2 B.1.351 strain in neutralizing 
titers
The percentage of participants with a seroresponse to the reference 
strain and to the B.1.351 strain (and corresponding 
2-sided Clopper-
Pearson 95% CI) will be provided b y vaccine group at 1 month after 
Dose 2 , before Dose 3, and 1week after and 1 month after Dose 3 (see 
Section 9.4.1.1).
* Seroresponse is defined as ≥4-fold increase from baseline (before Dose 1) to the specified time point. If the 
baseline measurement is below LLOQ, apostvaccination measure mentof ≥4 ×LLOQ is considered a 
seroresponse .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 809.6.Data Monitoring Committee or Other Independent Oversight Committee
This study  will use a DMC . TheDMC is independent of the study  team and includes 
external members.  The DMC charter describes the role of the DMC in more detail.
The DMC will be responsible for ongoing monitoring of the safety  of participants in the 
study  according to the charter .This may  include, but is not limited to:
Contemporaneous review of related AEs up to 1 month after completion of the 
vaccination schedule,
Contemporaneous review of all SAEs up to 1 month after completion of the 
vaccination schedule.
The recommendations made b y the DMC to alter the conduct of the stud y will be forwarded 
to the appropriate Pfizer personnel for fina l decision.  Pfizer will forward such decisions, 
which may  include summaries of aggregate analy ses of safety  data, to regulatory  authorities, 
as appropriate.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 8110.SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Stud y Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The prot ocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor and submitted to an 
IRB/EC by  the investigator and reviewed and approved by  the IRB/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by  
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable loc al regulations.
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately .
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investi gator becomes aware 
of.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 8210.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his or her parent(s)/legal guardian and answer all questions regarding the study .  
The participant or his or her parent(s)/legal guardian s
hould be given sufficient time and 
opportunity  to ask questions and to decide whether or not to participate in the trial. When
consent is obtained from a participant’s parent(s)/legal guardian, the participant’s assent 
(affirmative agreement) must be subsequently  obtained when the participant has the capacity  
to provide assent, as determined by  the IRB/EC.  If study  participants are minors who reach 
the age of majority  during the study , as recognized under local law, they  must be reconsented 
as adults to remain in the study .
Participants must be informed that their participation is voluntary .Participants or their
parent(s)/legal guardian will be required to sign a statement of informed consent that meets 
the requirements of 21 CFR 50, local regulations, ICH guidelines, HI PAA requirements, 
where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant or his or her parent(s)/legal guardian
is fully  informed about the nature and ob jectives of the study , the sharing of data related to 
the study ,
and possible risks associated with participation, including the risks associated with 
the processing of the participant’s personal data.
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant or his or her parent(s)/legal guardian .
The participant must be informed that his/her medical r ecords may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  partici pant or his or her parent(s)/legal 
guardian is fully  informed about his or her right to access and correct his or her personal data 
and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that wri tten informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most cu rrent version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant or his or her parent(s)/legal 
guardian.  Participants who are rescreened are required to sign a new IC D.
Unless prohibited by  local requirements or IRB/EC decision, t he IC Dwill contain a separate 
section that addresses the use of samples for optional additional research. The optional 
additional research does not require the collection of an y further samples.  The investigator 

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 83or authorized designee will explain to each participant the objectives of the additional
research. Participants will be told that they  are free to refuse to participate and may  
withdraw their consent at any  time and for any  reason during the storage period .
10.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropr iate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site will be responsible 
for determining whether a personal data breach has 
in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor will protect the confidentiality  of participants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.4. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations.  In addition, Pfize r reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of th e stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 84EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European U nion Policy  0070, the proactive publication of clinical 
data to the EMA website.  Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods.  Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data.  Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data Sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatis tician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.5. Data Quality Assurance
All participant data relating to the stud y will be recorde d on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 85The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical r isk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the 
monitoring plan.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of par ticipants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC Ds, perta ining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part
y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintaine d.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the ins pection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copies of the inspection findings to the spon sor or its agent.  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 8610.1.6. Source Documents
Source documents provide evid ence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the study  monitoring plan .
Description of the use of computerized sy stem is documented in the Data Management Plan .
10.1.7. Study and Site Start and Closure
The study  start date is the date on which the cl inical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the st udy at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit ha s been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee if requested to do so by  the responsible I RB/EC or if such termination is required 
to protect the health of study  participants .
Reas ons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 87Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.8. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in the supporting study  documentation
electronic s ystem.
To facilitate access to appropriatel y qualified medic al personnel on stud y-related medical 
questions or problems, participant s are provided with a contact card at the time of informed 
consent .  The contact card contains, at a minimum, protocol and study  intervention
identifiers, participant numbers, contact information for the investigator site, and contact 
details for a contact center in the event that the investigator site staff cannot be reached to 
provide advice on a medical question or problem originating from another healthcare 
professional not involved in the participant ’s participation in the study .  The contact number 
can also be used b y investigator staff if they are seeking advice on medical questions or 
problems; however, it should be used only
 in the event that the established communication 
pathwa ys between the investigator site and the study  team are not available.  I t is therefore 
intended to augment, but not replace, the established communication pathway s between the 
investigator site and the study  team for advice on medical questions or problem s that may  
arise during the stud y.  The contact number is not intended for use b y the participant directl y, 
and if a participant calls that number, he or she will be directed back to the investigator site.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 8810.2. Appendix 2: Clinical Laboratory Tests
Apregnancy  test will be performed at times defined in the SoA section of this protocol :  
Visit 1 (Vaccination 1/Day  1) and Visit 2 (Vaccination 2/19 -23 day s after Visit 1) .
Pregnancy  test (β -hCG):  Local urine testing will be standar d for the protocol unless 
serum testing is required by  local regulation or IRB/EC for female participants of 
childbearing potential.
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues.  Investigators must document their review of each 
laboratory  safet y report.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 91Hospitalization for elective treatment of a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and acc idental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in d eciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but may  
jeopardize the participant or may require medical or surgical inter vention to prevent 
one of the other outcomes listed in the above definition. These events should 
usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
Suspected transmission via a Pfizer product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious. The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 
Pfizer product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are considered unexpe cted and handled as 
serious expedited cases by pharmacovigilance personnel.  Such cases are also 
considered for reporting as product defects, if appropriate.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 9610.4. Appendix 4: Contraceptive Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28 day safter the last dose of stud y intervention ,which 
corresponds to the time needed to eliminat e reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person .
In addition to male condom use, a highl y effective method of contraception may be 
consider ed in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies :
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using an acceptable contraceptive method as described below 
during the intervention period (for a minimum of 28 day s after the last dose of study  
intervention).  The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervent ion.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 9710.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview.  The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2. Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  In addition, a
high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not usin
g hormonal 
contraception or HRT.
Female on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y.  Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 9810.4.4. Contraception Methods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion .
5.Vasectomized partner :
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly  effective method of contraception should be 
used. The s permatogenesis c ycle is approximately  90 day s.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation :
Oral;
Intravaginal;
Transdermal ;
Injectable .
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable .
8.Sexual abstinence :
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.   The reliability of sexual abstinence needs to be evaluated 
in relation to the duration of the study
 and the preferred and usual lifest yle of the 
participant.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 999.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10.Male or female condom with or without spermicide.
11. Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 10010.5. Appendix 5: Liver Safety: Suggested A ctions and Follow - up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  
In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adap tor” or are “susceptible.”
LFTs are not required as a routine safety  monitoring procedure in this study .  However, 
should an investigator deem it necessary  to assess LFTs because a participant presents with 
clinical signs/s ymptoms, such LFT results should be managed and followed as described 
below.
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2 ×ULN) b y several day s or weeks.  The increase in TBili ty pically  occurs while 
AST/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instances, by  the time TBili elevations 
are detected, AST/ALT values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abno rmal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible ca uses of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following laboratory  abnormal ities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller) .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 101Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soo n as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.
In addition to repeating measurements of AST and AL T and TBili for suspected case s of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase.  Consideration should 
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testing, as needed, for further contemporaneous anal yses at the time of the 
recognized initial abnormaliti
es to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  itself or as a 
coformulated product in prescription or over -the-counter medications) , recreational drug, 
suppleme nt (herbal) use and consumption, family  history , sexual history , travel history , 
history  of contact with a jaundiced person, surgery , blood transfusion, history  of liver or 
allergic disease, and potential occupational exposure to chemicals, should be colle cted.  
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  
tract) and collection of serum sample s for acetaminophen/paracetamol drug and/or protein 
adduct levels may be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) 
cases are to be re ported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations ha ve been received and have excluded an alternative etiology .

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 10210.6. Appendix 6: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
2019 -nCoV novel coronavirus 2019
ACIP Advisory  Committee on Immunization Practices
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
-hCG beta-human chorionic gonadotropin
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention (United States)
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRP C-reactive protein
CSR clinical study  report
DILI drug-induced liver injury
DMC data monitoring committee
DNA deox yribonucleic acid
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
e-diary electronic diary
EDP exposure during pregnancy
EMA European Medicines Agency
ESR erythrocy te sedimentation rate
EU European Union
EUA emergency  use authorization
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMC geometric mean concentration

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 103Abbreviation Term
GMFR geometric mean fold rise
GMR geometric mean ratio
HBV hepatitis B virus
HCV hepatitis C virus
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HRT hormone replacement therap y
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IgG immunoglobulin G
IL-6 interleukin -6
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB institutional review board
IRT interactive response technology
ISF investigator site file
IV intravenous(l y)
IWR interactive Web -based response
LDH lactate deh ydrogenase
LFT liver function test
LLOQ lower limit of quantitation
LNP lipid nanoparticle
LS least squares
MedDRA Medical Dictionary  for Regulatory  Activities
MERS Middle East respiratory  syndrome
MIS-C multisy stem i nflammatory  syndrome in children
modRNA nucleoside -modified messenger ribonucleic acid
N SARS -CoV -2 nucleoprotein
N/A not applicable
NAAT nucleic acid amplification test 
NIMP noninvestigational medicinal product
P2 S SARS -CoV -2 full -length, P2 mutant, prefusion spike gl ycoprotein
PCR polymerase chain reaction
PI principal investigator
PPE personal protective equipment
PT prothrombin time

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 104Abbreviation Term
RCDC reverse cumulative distribution curve
RNA ribonucleic acid
RSV respiratory  syncytial virus
RT-PCR reverse transcription–poly merase chain reaction
S spike protein
S1 spike protein S1 subunit
SAE serious adverse event
SAP statistical analy sis plan
SARS severe acute respiratory  syndrome
SARS -CoV -2 severe acute respiratory  syndrome coronavirus 2
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
SSID single subject identification
SUSAR suspected unexpected serious adverse reaction
TBili total bilirubin
Th 1 T-helper t ype 1
UK United Kingdom
ULN upper limit of normal
US United States
VOC variant of concern
WHO World Health Organization
WOCBP woman/women of childbearing potential

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 10511.REFERENCES
1Virus Pathogen Resource (ViPR). Strain details for severe acute respiratory sy ndrome -
related coronavirus strain Wuhan- Hu-1. Available from: 
https://www.viprbrc.org/brc/viprStrainDetails.spg?ncbiAccession=MN908947&decorat
or=corona .  Accessed: 11 Aug 2020.
2Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in 
China, 2019. N Engl J Med. 2020;382(8):727-33.
3World H ealth Organization. Timeline: WHO's COVID -19 response. Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/interactive -
timeline# !. Accessed: 08 Jan 2021.
4World Health Organization. WHO Director -General's opening remarks at the media 
briefing on COVID -19.Available from: https://www.who.int/dg/speeches/detail/
who-director -general -s-opening -remarks -at-the-media -briefing -on-covid -19--- 11-march -
2020. Published: 11 Mar 2020. Accessed: 01 Apr 2020.
5COVID -19 dashboard by the Center for S ystems Science and Engineering (CSSE) at 
Johns Hopkins University.  Available from: 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299
423467b48e9ecf6 .Accessed: 08 Jan 2021.
6Centers for Disease Control and Prevention. Emerging SARS -CoV -2 variants. Available 
from: https://www.cdc.gov/coronavirus/2019 -ncov/more/science -and-
research/scientific -brief -emerging -variants.html. Updated: 28 Jan 2021. Accessed: 
10Feb 2021.
7Rauch S, Jasny  E, Schmidt KE, et al. New vaccine tec hnologies to combat outbreak 
situations. Front I mmunol. 2018;9:1963.
8Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of 
drugs. Nat Rev Drug Discov. 2014;13(10):759 -80.
9BioNTech RNA Pharmaceuticals GmbH. CorVAC/BNT162 Investi gator’s Brochure. 
Mainz, German y: BioNTech RNA Pharmaceuticals GmbH; 25 Mar 2020.
10Feldman RA, Fuhr R, Smolenov I , et al. mRNA vaccines against H10N8 and H7N9 
influenza viruses of pandemic potential are immunogenic and well tolerated in healthy  
adults in 
phase 1 randomized clinical trials. Vaccine .2019;37(25):3326 -34.
11BioNTech RNA Pharmaceuticals GmbH. BNT162/PF -07302048 Investigator’s 
Brochure. Mainz, Germany : BioNTech RNA Pharmaceuticals GmbH; 29 Jan 2021.

PF-07302048 (BNT162b2 RNA -Based COVID -19 Vaccine)
Protocol C459 1017
Final Protocol Amendment 2, 03 May 2021
PFIZER CONFIDENTIAL
Page 10612US Food and Drug Administration. Guidance f or industry : toxicity  grading scale for 
healthy  adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
Rockville, MD: Center for Biologics Evaluation and Research; September 2007.
13Centers for Disease Control and Prevention. Multisy stem inflammatory  syndrome in 
children (MIS -C) associated with coronavirus disease 2019 (COVID-19).  Available 
from:  https://emergency .cdc.gov/han/2020/han00432.asp.  Updated:  14 May  2020.  
Accessed:  15 Jan 2021.
14Centers for Disease Control and Prevention.  Sy mptoms of COVI D-19.  Available from: 
https://www.cdc.gov/coronavirus/2019- ncov/s ymptoms -testing/sy mptoms.html.  
Updated: 22 Feb 2021. Accessed: 29 Apr 2021.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	
	 

      
  
	
'RFXPHQW 7LWOH	
	 

   
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\

$$
	 	%% &#'
'' 
 (

$$
	 
%

%	 *
 (PPD
PPD